<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stem cell transplantation for induction of remission in medically refractory Crohn’s disease - El-Nakeep, S - 2022 | Cochrane Library</title> <meta content="Stem cell transplantation for induction of remission in medically refractory Crohn’s disease - El-Nakeep, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013070.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stem cell transplantation for induction of remission in medically refractory Crohn’s disease - El-Nakeep, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013070.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013070.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Stem cell transplantation for induction of remission in medically refractory Crohn’s disease" name="citation_title"/> <meta content="Sarah El-Nakeep" name="citation_author"/> <meta content="Faculty of Medicine, Ain Shams University" name="citation_author_institution"/> <meta content="sarahnakeep@gmail.com" name="citation_author_email"/> <meta content="Ahmed Shawky" name="citation_author"/> <meta content="Faculty of Medicine, Ain Shams University" name="citation_author_institution"/> <meta content="Sara F Abbas" name="citation_author"/> <meta content="Faculty of Medicine, Ain Shams University" name="citation_author_institution"/> <meta content="Osama Abdel Latif" name="citation_author"/> <meta content="Faculty of Medicine, Ain Shams University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013070.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013070.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013070.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013070.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Constriction, Pathologic; *Crohn Disease [drug therapy]; *Hematopoietic Stem Cell Transplantation; Inflammation; Remission Induction" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013070.pub2&amp;doi=10.1002/14651858.CD013070.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="SVRJ5zHF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013070\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013070\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013070.pub2",title:"Stem cell transplantation for induction of remission in medically refractory Crohn\\u2019s disease",firstPublishedDate:"May 13, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013070.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013070.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013070.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013070.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013070.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013070.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013070.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013070.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013070.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013070.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2225 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013070.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/appendices#CD013070-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/supinfo/CD013070StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/supinfo/CD013070StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stem cell transplantation for induction of remission in medically refractory Crohn’s disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#CD013070-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sarah El-Nakeep</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#CD013070-cr-0005">Ahmed Shawky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#CD013070-cr-0006">Sara F Abbas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information#CD013070-cr-0007">Osama Abdel Latif</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information/en#CD013070-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013070.pub2">https://doi.org/10.1002/14651858.CD013070.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013070-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013070-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013070-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013070-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013070-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013070-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013070-abs-0001" lang="en"> <section id="CD013070-sec-0001"> <h3 class="title" id="CD013070-sec-0001">Background</h3> <p>Crohn's disease (CD) is an inflammatory bowel disease that causes inflammation and stricture, of any part of the mucosa and the gut wall. It forms skip lesions, sparing the areas in between the affected parts of the gastrointestinal tract. Crohn's disease could have one of three complications; fistula, intestinal obstruction due to stricture, or gastrointestinal inflammation presenting as severe diarrhoea. </p> <p>Stem cell therapy (SCT) is an innovative treatment that has been recently used in CD. The exact role of SCT in CD is still unclear. Stem cells modify the immunity of the patients or act as a “reset tool” for the immune system as in the case of systemically‐injected stem cells, or regenerate the affected area of necrotic and inflammatory tissue as in the case of local injection into the lesion. Stem cells are a wide variety of cells including pluripotent stem cells or differentiated stem cells. The hazards range from rejection to symptomatic manifestations as fever or increase infection.  </p> </section> <section id="CD013070-sec-0002"> <h3 class="title" id="CD013070-sec-0002">Objectives</h3> <p>The objective of this Cochrane systematic review is to assess the effects of stem cell transplantation compared to standard of care alone or with placebo on efficacy and safety outcomes in patients with refractory CD. </p> </section> <section id="CD013070-sec-0003"> <h3 class="title" id="CD013070-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trial registries (Clinicaltrials.gov, World Health Organization‐International Clinical Trials Registry Platform WHO ICTRP) from inception to 19 March 2021, without any language, publication year, or publication status restrictions. In addition, we searched references of included studies and review articles for further references. An update of the published studies was done during the writing of the review. </p> </section> <section id="CD013070-sec-0004"> <h3 class="title" id="CD013070-sec-0004">Selection criteria</h3> <p>We included only randomised controlled trials (RCTs) that assessed the effectiveness and safety of SCT in refractory CD versus standard care alone (control) or with placebo. </p> </section> <section id="CD013070-sec-0005"> <h3 class="title" id="CD013070-sec-0005">Data collection and analysis</h3> <p>Two review authors (SEN and SFA) independently screened the studies retrieved from the search results for inclusion, extracted data and assessed the risk of bias. Any disagreement was resolved through a consensus between the authors. We used standard methodological procedures expected by Cochrane. </p> </section> <section id="CD013070-sec-0006"> <h3 class="title" id="CD013070-sec-0006">Main results</h3> <p>We conducted our search on 19 March 2021 and identified 639 records. We added two records by a manual search of the published reviews on the topic to a total of 641 records. The Covidence program removed 125 duplicates making a total of 516 reports. Two review authors (SEN and SFA) screened titles and abstracts and excluded 451 records with the remaining 65 for full‐text records screened independently by the two authors; only 18 studies were considered for inclusion.  </p> <p>We included seven RCTs with a total of 442 participants for the meta‐analysis. The intervention group included 234 patients, and the control group included 208 patients. Nine trials are ongoing and, two abstracts are awaiting classification. </p> <p>All patients in the control and intervention groups received the standard therapy for CD. Only three studies used blinding methods for the control group in the form of a placebo, with one study of the three stated that the blinding method was inefficient. The patients and personnel were aware of the intervention in the rest of the four studies as they were open‐label trials. However, the effect of unblinding was balanced by the low risk of detection bias in five of the included studies. </p> <p>The evidence is uncertain about the effect of SCT on achieving clinical remission as compared to control/placebo (risk ratio (RR) 1.88, 95% Confidence Interval (CI) 0.80 to 4.41; 3 studies; low‐certainty evidence). </p> <p>The evidence is very uncertain about the effect of SCT on achieving Crohn’s Disease Activity Index (CDAI) &lt;150 at 24 weeks compared to control (RR1.02 95% CI 0.67 to 1.56; 4 studies; very‐low certainty evidence). </p> <p>SCT is likely to achieve fistula closure as compared to the control/placebo both in the short term (RR 1.48, 95% CI 1.12 to 1.96); low‐certainty evidence) and in the long term (RR 1.42, 95% CI 1.09 to 1.87; 4 studies; low‐certainty evidence) follow‐up. </p> <p>The evidence is very uncertain about the effect of SCT to cause no difference in the number of total adverse events as compared to the control/placebo (RR 0.99, 95% CI [0.88 to  1.13); 4 studies; very‐low‐certainty evidence). However, SCT is likely to increase the number of serious adverse events as compared to the control/placebo (RR 1.22, 95% CI 0.88 to 1.67; 7 studies; low‐certainty evidence). </p> <p>The evidence is very uncertain about the effect of SCT to decrease the withdrawal due to adverse events as compared to the control/placebo (RR 0.78, 95% CI 0.32 to 1.89; 3 studies; very‐low certainty evidence). </p> <p>Funding by pharmaceutical companies was found in three studies, with one including more than 50% of our studied population. </p> </section> <section id="CD013070-sec-0007"> <h3 class="title" id="CD013070-sec-0007">Authors' conclusions</h3> <p>SCT shows an uncertain effect on clinical remission with low certainty of evidence. SCT shows an uncertain effect on CDAI score to reach &lt;150 after 24 weeks of treatment, with very low certainty evidence. SCT shows beneficial effects on fistula‐closure during short and long‐term follow‐up with low‐certainty evidence in both outcomes. There was no change in the total number of adverse events with SCT as compared to control, with very low certainty evidence. While there was a moderate effect on increasing the number of serious adverse events in the SCT group, as compared to the control with low‐certainty evidence. Withdrawal due to adverse events was slightly higher in the control group with very low certainty evidence. </p> <p>All the participants were refractory to standard medical treatment, but the number of participants was small, this may limit the generalizability of the results. Further research is needed for validation. More objective outcomes are needed in the assessment of stem cell effectiveness in the treatment of Crohn's disease, especially the intestinal CD subtype; with standardization of the dose, methods of stem cell preparation, route of administration, and inclusion criteria to the studies to achieve clear results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013070-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013070-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013070-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013070-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013070-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013070-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013070-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013070-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013070-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013070-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013070-abs-0002" lang="en"> <h3>Stem cells for treating patients not responding to Crohn's disease treatment</h3> <p><b>Question</b> </p> <p>Are stem cells (SCs) an effective and safe option in patients with Crohn's disease (CD) when they do not respond to their standard medical treatment?  </p> <p><b>Key messages</b> </p> <p>Stem cells when combined with standard medical treatment could be better than the medical treatment alone or with a placebo (a dummy treatment) in the healing of the opening in the perianal region connected to the bowels caused by CD (perianal fistula). </p> <p>Stem cells when combined with standard medical treatment could be safe when compared to the medical treatment alone or with a placebo in treating the bowel inflammation associated with Crohn's disease (total and serious adverse events). </p> <p><b>What are stem cells?</b>  Stem cells are the cells responsible for forming new cells and renewing the surrounding tissue. They are also responsible for modifying the immune system. There are various types of SCs, self‐stem cells extracted from the patient's own body (autologous) and non‐self stem cells extracted from other individuals (allogeneic). They could be found in the bone marrow, fat tissue, placenta, umbilical vein, etc.  </p> <p><b>What is Crohn's disease?</b> It is an autoimmune (fighting the patient's own body) disease‐causing inflammation and stenosis of the bowel, or causing a bowel opening in the skin (fistula). CD usually follows an "on and off" pattern, it also affects the mortality, morbidity, and quality of life of the patients. Standard treatment of CD includes drugs that suppress the immunity of the patient including anti‐inflammatory, immunosuppressive, and biological drugs. However, one‐third of patients do not respond to medical or surgical treatment.  </p> <p><b>Why was this Cochrane Review conducted?</b> To assess if SCs are effective and safe in patients with CD who do not respond to medical treatment (i.e. refractory CD).  </p> <p><b>What did we do?</b> We assessed randomised controlled trials on the topic. </p> <p><b>How up to date is this evidence?</b> </p> <p>This evidence is up‐to‐date to March 2021.</p> <p><b>What did we find?</b> </p> <p>We found seven trials on the topic, including 442 patients (234 in the stem cell group and 208 in the placebo or control groups). The follow‐up duration in the studies varied from one to four years. We included seven RCTs with a total of 442 participants for the meta‐analysis. The intervention group included 234 patients, and the control group included 208 patients.  We assessed the effect of both the systemic and local administration of SCs. The intervention group included 127 males (55.95%) and 100 females (44.05%), while the control/placebo group included 114 males (56.44%) and 88 females (43.56%). Studies were conducted in the UK, China, Spain, the Netherlands, and the USA. </p> <p>We found data on clinical remission in  three studies, data on achieving Crohn's Disease Activity Index (CDAI) &lt;150 after 24 weeks in three studies, data on fistula closure short and long term in four studies, data on the total number of adverse events in four studies, data on serious adverse events in seven studies, and data on withdrawal due to adverse events in three studies. </p> <p><b>What are our main results?</b> </p> <p>In patients who did not respond to standard medical treatment for CD, we found that: when using SCs combined with medical treatment compared to medical treatment alone or with placebo, it is unclear whether they cause an achievement of improvement in the clinical remission, or in the clinical score CDAI to &lt;150 after 24 weeks. SCs combined with medical treatment, when compared to the standard medical treatment, are likely to lead to improvement in the rate of fistula closure in both the short and long term. SCs combined with medical treatment, when compared to the standard medical treatment, are less likely to change the number of total adverse events. SCs combined with medical treatment, when compared to the standard medical treatment, are more probable to increase the number of occurrences of serious adverse events, but are less likely to decrease the number of patients who withdrew due to adverse events.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Three of the included trials were funded by pharmaceutical companies. </p> <p>Only a small number of studies addressed the topic with small numbers of patients. Moreover, most of the studied population (&gt; 60%) was in those funded three studies, with one study including &gt;50% of the studied population. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013070-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013070-sec-0091"></div> <h3 class="title" id="CD013070-sec-0092">Implications for practice</h3> <section id="CD013070-sec-0092"> <p>Stem cell therapy, when injected systemically, is uncertain to produce benefit or harm on achieving improvement in clinical remission( the data are uncertain) or CDAI score &lt;150 at 24 weeks (the data are very uncertain), for the treatment of refractory CD. Stem cell therapy could have a beneficial effect when injected locally, on the achievement of fistula closure in the short and long terms (the data are uncertain). The stem cells may cause no effect on the number of total adverse events (the data are very uncertain). Moreover, SCs may increase the number of serious adverse events (the data are uncertain). The withdrawal due to adverse events may be decreased by stem cell therapy (the data are very uncertain). </p> </section> <h3 class="title" id="CD013070-sec-0093">Implications for research</h3> <section id="CD013070-sec-0093"> <p>The effect on modifying and "resetting" the immune system didn't have enough clinical and laboratory data to support it, and further studies are needed to confirm or refute its benefit. We need a more clear and unified definition of clinical remission for future clinical trials. CDAI score as the primary outcome could be misleading due to its subjectivity and a more objective score could be more consistent. </p> <p>Large‐scale randomized trials are needed to validate the efficacy and effectiveness of stem cells in the treatment of refractory Crohn's disease. Standardization of the doses, outcome measures, and patients' selection criteria will lead to more consistent and clear results. </p> <p>The effect of SCT on other forms of IBD mainly UC needs to be further evaluated.</p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013070-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013070-sec-0008"></div> <div class="table" id="CD013070-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn?s Disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn's Disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Induction of Remission in Medically Refractory Crohn's Disease<br/><b>Setting:</b> Specialised centres<br/><b>Intervention:</b> Stem Cell<br/><b>Comparison:</b> Placebo or Control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Placebo or Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Stem Cell</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(252 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/>(0.80 to 4.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The three studies that included data about clinical remission were Hawkey 2015, Melmet 2015, and Panes 2016. Each had a different definition of clinical remission. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &lt;150 at 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(339 to 789) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data regarding the CDAI at 24 weeks was not the primary outcome of any of the included studies. They also used different cut‐offs and different ranges. Here we included local and systemic stem cell therapy. Zhang et al 2018 had zero weight, as the number of events was 0 in both intervention and control arms (the authors stated that no patients achieved CDAI &lt;150 at 24 weeks). The baseline CDAI was already low in the studies examining fistula management. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula Closure short‐term<br/>assessed with: Clinically or MRI </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>349 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(391 to 684) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.48</b><br/>(1.12 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula closure was assessed in four studies. Garcia‐Olmo et al 2009 assessed the outcome at 8 weeks, while Molendijk et al 2015, Panes et al 2016, and Zhou et al 2020 assessed the outcome at 24 weeks. It was assessed both clinically and with MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula closure in long‐term Follow up of original studies<br/>assessed with: Clinicaaly or MRI </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b><br/>(425 to 729) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b><br/>(1.09 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>h,</sup><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data on the long‐term effects were gathered from published papers after a long‐term follow‐up of the original studies. Except Zhou 2020, which reported their long‐term 1‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total Adverse Events<br/>assessed with: Clinically </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>730 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>723 per 1000</b><br/>(643 to 825) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.88 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,</sup><sup>k,</sup><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The range of total adverse effects stated was very wide across studies, from minimal abdominal pain or low‐grade fever to sepsis and the need for surgical operation. We collected the data on total adverse events without stating the level, or severity of the adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious Adverse Events<br/>assessed with: Clinically </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b><br/>(99 to 187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b><br/>(0.88 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>m,</sup><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 7 studies stated the number of patients suffering from serious adverse effects, mostly because these trials are addressing the safety issues of stem cell administration. The different definitions of serious adverse events among the studies make the outcome assessment heterogeneous and inconsistent, some studies did not define clearly what a serious adverse event stands for. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b><br/>(24 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b><br/>(0.32 to 1.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>o,</sup><sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both Panes 2016 and Zhou 2020 stated clearly that the withdrawal was due to adverse events. But in Hawkey 2015, it was stated that one patient from the control group withdrew directly after randomization, and one patient in the active group withdrew after 26 weeks of mobilization for accelerated transplantation. In Zhou 2020, the patients withdrew due to adverse effects to receive a subsequent reoperation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423896885310176737" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423896885310176737</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The risk of bias is downgraded to serious, as two of the three studies are open‐label, thus the participants are not blinded including Panes 2016 which contains most of the studied population, and this outcome is a subjective outcome.<br/><sup>b</sup> The inconsistency was downgraded by one level as the heterogeneity in the included studies was high in the form of the variability of the results due to different definitions of the outcome.<br/><sup>c</sup> Inconsistency downgraded by one level to serious as the level of CDAI at the start of the studies varied according to the route of intervention, CDAI was low or normal at baseline in local intervention, while high at baseline in systemic intervention.<br/><sup>d</sup> The imprecision was downgraded by one level to serious as the RR is 1.08 with CI 0.94‐1.24, which makes the intervention equally capable of doing harm or benefit.<br/><sup>e</sup> Publication bias strongly suspected and downgraded by one level as there were two abstracts of unpublished complete data (Arturo 2017 and Lichtiger 2012).<br/><sup>f</sup> The outcome was downgraded by one point to serious as the risk of allocation concealment was unclear in three studies (Garcia‐Olmo 2009 and Zhou 2020), and randomization was unclear in (Zhou 2020). Although the risk of bias for blinding of participants is high in (Zou 2020, Panes 2016, Garcia‐Olmo 2009), and unclear in (Molendijk 2015); three of these studies had a low risk for detection bias, while only Zhou 2020 had high risk. Also, the outcome is an objective outcome that doesn't change by the participant or the personnel being unblinded.<br/><sup>g</sup> Imprecision was downgraded by one level to serious as the number of the studied population was small.<br/><sup>h</sup> The risk of bias is downgraded to serious: as there are a lot of patients lost to long‐term follow‐up (missing data), thus high attrition.<br/><sup>i</sup> The imprecision was downgraded by one level to serious as the number of patients and number of events were low. Also, the confidence interval was wide.<br/><sup>j</sup> The risk of Bias was downgraded by one level to serious as three of the four studies had a high risk of performance bias and one unclear risk. Considering that the outcome is reporting about the adverse events, which are mostly subjective in the case of mild and moderate adverse events, we downgraded by one level.<br/><sup>k</sup> Inconsistency is downgraded by one level to serious as the studies reported the category (All adverse events differently)<br/><sup>l</sup> Impression was downgraded by one level as the number of participants was low<br/><sup>m</sup> The risk of bias was downgraded by one level, as 5 trials had high‐performance bias (open‐label trials) but it is not an objective outcome, and allocation concealment is unclear in 4 trials and randomization is unclear in 2 trials.<br/><sup>n</sup> Imperceision is downgraded by one level to serious because the CI was very wide (0.89‐1.93), so we are not certain if the intervention causes benefit or harm. <br/><sup>o</sup> Indirectness was downgraded by one level to seriuos as the causes of withdrawal in (Hawkey 2015) were not stated as due to adverse events.<br/><sup>p</sup> Imprecision was downgraded by two levels to very serious due to the low number of participants and wide CI (0.33‐1.91), so we are not confident if the intervention causes benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013070-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013070-sec-0009"></div> <p>Crohn's disease (CD) is one of the inflammatory diseases affecting the gut. The autoimmune origins are apparent in the pathogenic mechanism of the disease. Its clinical manifestation includes diarrhoea, intestinal fistulas, and strictures. The disease follows a relapsing and remitting pattern in most cases. Refractory CD was previously defined as a persistently symptomatic acute CD or actively chronic CD, not responding to medical anti‐inflammatory treatment, and not reaching remission (<a href="./references#CD013070-bbs2-0116" title="Tremaine WJ .Refractory IBD: medical management. Netherlands Journal of Medicine1997;50(2):S12-S14.">Tremaine 1997</a>). The recent definition states that refractory CD is the failure of response to all licensed medical therapeutic approaches, while refractory perianal CD fistula means failure of at least one surgical therapeutic approach and anti‐tumour necrosis factor‐alpha (<a href="./references#CD013070-bbs2-0103" title="TimR , BramV , UriK , KonstantinosK , RimmaG , RajaA , et al.ECCO topical review: refractory inflammatory bowel disease. Journal of Crohns and Colitis2021;15(10):1605-20.">Raine 2021</a>). Refractory disease to the current medical treatment is present in a considerable number of cases (<a href="./references#CD013070-bbs2-0095" title="NgSC , ShiHY , HamidiN , UnderwoodFE , TangW , BenchimolEI , et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet2017;390(10114):2769-78.">Ng 2017</a>; <a href="./references#CD013070-bbs2-0073" title="Ha F KhalilH .Crohn's disease: a clinical update. Therapeutic Advances in Gastroenterology2015;8(6):352-9.">Ha 2015</a>; <a href="./references#CD013070-bbs2-0047" title="CarvelloM , LightnerA , YamamotoT , KotzePG , SpinelliA .Mesenchymal stem cells for perianal Crohn's disease. Cells2019;8(7):764.">Carvello 2019</a>). </p> <p>Stem Cells are an innovative tool to induce immunomodulatory response and reset the immune system. They could also act as a regenerative tool to induce the healing of tissues. Stem cells can be used as a local injection on‐site of the lesion or as a systemic infusion(<a href="./references#CD013070-bbs2-0110" title="RuizMA , KaiserJRL , Piron-RuizL , Peña-ArciniegasT , SaranPS , De QuadrosLG .Hematopoietic stem cell transplantation for Crohn's disease: Gaps, doubts and perspectives. World Journal of Stem Cells2018;10(10):134-7.">Ruiz 2018</a>). </p> <section id="CD013070-sec-0010"> <h3 class="title" id="CD013070-sec-0010">Description of the condition</h3> <p>Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract that typically affects young adults between 15 and 35 years of age. The prevalence of Crohn's disease is nearly 320 per 100,000, with the highest prevalence in Europe and North America. The prevalence of Crohn's disease in developing countries might be underestimated due to a lack of rigorous population screening studies (<a href="./references#CD013070-bbs2-0094" title="MolodeckyNA , SoonIS , RabiDM , GhaliWA , FerrisM , ChernoffG , et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142(1):46-54.">Molodecky 2012</a>; <a href="./references#CD013070-bbs2-0095" title="NgSC , ShiHY , HamidiN , UnderwoodFE , TangW , BenchimolEI , et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet2017;390(10114):2769-78.">Ng 2017</a>). </p> <p>Crohn's disease presents mainly with abdominal pain, diarrhoea, fever, malabsorption, and weight loss (<a href="./references#CD013070-bbs2-0038" title="AbrahamC , ChoJH .Inflammatory bowel disease. New England Journal of Medicine2009;361(21):2066-78.">Abraham 2009</a>; <a href="./references#CD013070-bbs2-0109" title="RuizMA , KaiserJRL , GouveaFMA , deQuadrosLG .Remission of refractory Crohn's disease after autologous hematopoietic stem cell transplantation. Revista Brasileira de Hematologia e Hemoterapia2015;37(2):136-9.">Ruiz 2015</a>). Crohn's disease causes both mucosal and transmural inflammation that can affect any part of the gastrointestinal tract, but mostly the small bowel (<a href="./references#CD013070-bbs2-0119" title="WiardaBM , MensinkPB , HeineDG , StolkM , DeesJ , HazenbergH , et al.Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. Abdominal Imaging2012;37(3):397-403.">Wiarda 2012</a>). There are three Crohn's disease behaviours (Montreal classification) that can occur at any time during the disease course. These are non‐stricturing, non‐penetrating, stricturing and penetrating disease (<a href="./references#CD013070-bbs2-0112" title="SatsangiJ , SilverbergMS , VermeireS , ColombelJF .The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut2006;55(6):749–53.">Satsangi 2006</a>). Common complications of Crohn's disease include perianal fistulae and abscesses. Some patients may have immune‐mediated extraintestinal manifestations (i.e. arthritis, eye, skin, and liver) (<a href="./references#CD013070-bbs2-0079" title="IseneR , BernklevT , HoieO , MunkholmP , TsianosE , StockbruggerR , et al.Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scandinavian Journal of Gastroenterology2015;50(3):300-5.">Isene 2015</a>; <a href="./references#CD013070-bbs2-0100" title="Peyrin-BirouletL , VanAG , Gomez-UlloaD , Garcia-AlvarezL , LaraN , BlackCM , et al.Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clinical Gastroenterology and Hepatology2017;15(1):25-36.e27.">Peyrin‐Biroulet 2017</a>). Crohn's disease follows a relapsing and remitting course (<a href="./references#CD013070-bbs2-0097" title="NikfarS , Ehteshami-AfsharS , AbdollahiM .Is Certolizumab pegol safe and effective in the treatment of patients with moderate to severe Crohn's disease? A meta-analysis of controlled clinical trials. Iranian Red Crescent Medical Journal2013;15(8):668-75.">Nikfar 2013</a>). The therapeutic goal of treatment is to induce and maintain clinical remission. Different interventions have been investigated for inducing remission in active Crohn's disease (<a href="./references#CD013070-bbs2-0058" title="DassopoulosT , SultanS , Falck–YtterYT , InadomiJM , HanauerSB .American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology2013;145(6):1464-78.">Dassopoulos 2013</a>). </p> </section> <section id="CD013070-sec-0011"> <h3 class="title" id="CD013070-sec-0011">Description of the intervention</h3> <p>Stem cell therapy includes haematopoietic stem cells (HSCs) and mesenchymal stem (stromal) cells (MSCs). Stem cell therapy, whether HSCs or Mesenchymal stem cells (MSCs), can be subdivided into autologous donation (isolated from the patient) or allogenic donation (isolated from a donor, ideally human leukocyte antigen matched) (<a href="./references#CD013070-bbs2-0057" title="DalalJ , GandyK , DomenJ .Role of mesenchymal stem cell therapy in Crohn's disease. Pediatric Research2012;71(4 Pt 2):445-51.">Dalal 2012</a>; <a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>). </p> <p>HSCs can be administered by an intra‐arterial or intravenous approach (<a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>). HSCs are characterised by their differentiation abilities into multi lineage cell types, and their migration to the affected tissues under the control of chemokines (<a href="./references#CD013070-bbs2-0108" title="RossiL , ChallenGA , SirinO , Lin KK-Y, GoodellMA .Hematopoietic stem cell characterization and isolation. Methods in Molecular Biology (Clifton, N.J.)2011;750:47-59.">Rossi 2011</a>). MSCs can be successfully isolated for clinical application from bone marrow, umbilical cord blood, or adipose tissue. MSCs can be administered by an intra‐arterial or intravenous route or by local injection (<a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>). Darvadstrocel is the first MSC to be approved by European guidelines for use in CD. It was approved after the results of the ADMIRE‐CD trial which showed a positive healing effect on the CD‐associated fistula. Darvadstocel is recommended for use only in refractory CD, after the failure of one or more of the standard therapies in adult patients (<a href="./references#CD013070-bbs2-0114" title="Scott LesleyJ .Darvadstrocel: a  review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs2018;32(6):627-34.">Scott 2018</a>). </p> <section id="CD013070-sec-0012"> <h4 class="title">Comparator intervention (standard of care)</h4> <p>These interventions include systemic corticosteroids such as hydrocortisone or prednisolone (<a href="./references#CD013070-bbs2-0042" title="BenchimolEI , SeowCH , SteinhartAH , GriffithsAM .Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006792. [DOI: 10.1002/14651858.CD006792.pub2]">Benchimol 2008</a>), locally‐acting corticosteroids such as budesonide (<a href="./references#CD013070-bbs2-0106" title="RezaieA , KuenzigME , BenchimolEI , GriffithsAM , OtleyAR , SteinhartAH , et al.Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD000296. [DOI: 10.1002/14651858.CD000296.pub4]">Rezaie 2015</a>), sulphasalazine (<a href="./references#CD013070-bbs2-0090" title="Lim W-C, WangY , MacDonaldJK , HanauerS .Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD008870. [DOI: 10.1002/14651858.CD008870.pub2]">Lim 2016</a>), tumour necrosis factor‐alpha (TNF‐α) antagonists such as infliximab (<a href="./references#CD013070-bbs2-0081" title="KawalecP , MikrutA , WiśniewskaN , PilcA .Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Archives of Medical Science2013;9(5):765-79.">Kawalec 2013</a>), azathioprine (<a href="./references#CD013070-bbs2-0050" title="ChandeN , TownsendCM , ParkerCE , MacDonaldJK .Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD000545. [DOI: 10.1002/14651858.CD000545.pub5]">Chande 2016</a>), interleukin inhibitors e.g. ustekinumab (<a href="./references#CD013070-bbs2-0091" title="MacDonaldJK , NguyenTM , KhannaR , TimmerA .Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD007572. [DOI: 10.1002/14651858.CD007572.pub3]">MacDonald 2016</a>), methotrexate (<a href="./references#CD013070-bbs2-0092" title="McDonaldJW , WangY , TsoulisDJ , MacDonaldJK , FeaganBG .Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD003459. [DOI: 10.1002/14651858.CD003459.pub4]">McDonald 2014</a>) and alpha‐4 integrin monoclonal antibodies such as vedolizumab (<a href="./references#CD013070-bbs2-0111" title="SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al.Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711-21.">Sandborn 2013</a>). Unfortunately, the only therapy that showed a positive effect on fistula healing after one year of follow‐up is infliximab with a success rate approaching 23% (in the Sands' clinical trial) (<a href="./references#CD013070-bbs2-0072" title="GuadalajaraH , García-ArranzM , HerrerosMD , Borycka-KiciakK , LightnerAL , García-OlmoD .Mesenchymal stem cells in perianal Crohn’s disease. Techniques in Coloproctology2020;24(8):883-9.">Guadalajara 2020</a>). Also, retreatment with anti‐TNF showed a lower response in both induction and maintenance of remission (<a href="./references#CD013070-bbs2-0101" title="PockleyAG , LindsayJO , FouldsGA , RutellaS , GribbenJG , AlexanderT , et al.Immune reconstitution after autologous hematopoietic stem cell transplantation in Crohn's disease: current status and future directions. A review onbBehalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Frontiers In Immunology2018;9:646.">Pockley 2018</a>). </p> <p>Immunosuppressive drugs are the standard treatment for CD. For those who do not respond or lose response to this therapy, treatment solutions become a challenge (<a href="./references#CD013070-bbs2-0055" title="CooperJ , BlakeI , LindsayJO , HawkeyCJ .Living with Crohn's disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study). BMJ Open2017;7(9):e015201.">Cooper 2017</a>). Further, endoscopic recurrence the following surgery may occur in up to 70% of cases (<a href="./references#CD013070-bbs2-0060" title="DayAS , BurgessL .Exclusive enteral nutrition and induction of remission of active Crohn's disease in children. Expert Review of Clinical Immunology2013;9(4):375-83.">Day 2013</a>; <a href="./references#CD013070-bbs2-0084" title="LawranceIC .What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?World Journal of Gastroenterology2014;20(5):1248-58.">Lawrance 2014</a>). </p> </section> </section> <section id="CD013070-sec-0013"> <h3 class="title" id="CD013070-sec-0013">How the intervention might work</h3> <p>The goal in treating CD is to achieve remission and halt any ongoing disease progression (<a href="./references#CD013070-bbs2-0069" title="GomollónF , DignassA , AnneseV , TilgH , Van AsscheG , LindsayJO , et al.3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis2017;11(1):3-25.">Gomollón 2017</a>). Stem cells have immunoregulatory potential. Therefore, stem cell therapy, either haematopoietic or mesenchymal, may induce remission in refractory CD (<a href="./references#CD013070-bbs2-0057" title="DalalJ , GandyK , DomenJ .Role of mesenchymal stem cell therapy in Crohn's disease. Pediatric Research2012;71(4 Pt 2):445-51.">Dalal 2012</a>; <a href="./references#CD013070-bbs2-0059" title="DaveM , MehtaK , LutherJ , BaruahA , DietzAB , Faubion WA Jr.Mesenchymal stem cell Therapy for inflammatory bowel disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases2015;21(11):2696-707.">Dave 2015</a>; <a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>; <a href="./references#CD013070-bbs2-0107" title="RicartE , Jauregui-AmezagaA , OrdasI , PinoS , RamirezAM , PanesJ .Cell therapies for IBD: what works?Current Drug Targets2013;14(12):1453-9.">Ricart 2013</a>). </p> <p>Haematopoietic stem cells (HSCs) extend immune modulation and suppression by incrementing immune suppression to the point of immune ablation(<a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>). Thus, HSCs can induce remission of the refractory CD through different mechanisms; either ablation of the bone marrow cells in the conditioning phase, which causes the destruction of the bone marrow cells, or later when the bone marrow restores its function and resetting of the cells occurs. Thymic reactivation is the key for cellular restoration in this phase for the T, B, plasma, and natural killer cells progeny (<a href="./references#CD013070-bbs2-0043" title="BrierleyCK , Castilla-LlorenteC , LabopinM , BadoglioM , RoviraM , RicartE , et al, and European Society for Blood and Marrow Transplantation [EBMT] Autoimmune Diseases Working Party [ADWP].Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis2018;12(9):1097-103.">Brierley 2018</a>). </p> <p>The role of HSCs in treating inflammatory bowel disease was originally supported by clinical remissions observed in patients undergoing stem cell transplant for haematological disorders. These observations led to trials of HSCs in patients with refractory CD (<a href="./references#CD013070-bbs2-0044" title="BurtRK , TraynorA , OyamaY , CraigR .High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood2003;101(5):2064-6.">Burt 2003</a>; <a href="./references#CD013070-bbs2-0045" title="BurtRK , CraigRM , MilanettiF , QuigleyK , GozdziakP , BuchaJ , et al.Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood2010;116(26):6123-32.">Burt 2010</a>; <a href="./references#CD013070-bbs2-0048" title="CassinottiA , AnnaloroC , ArdizzoneS , OnidaF , Della VolpeA , ClericiM , et al.Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut2008;57(2):211-7.">Cassinotti 2008</a>; <a href="./references#CD013070-bbs2-0054" title="ClericiM , CassinottiA , OnidaF , TrabattoniD , AnnaloroC , Della VolpeA , et al.Immunomodulatory effects of unselected hematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease2011;43(12):946-52.">Clerici 2011</a>; <a href="./references#CD013070-bbs2-0056" title="CraigRM , TraynorA , OyamaY , BurtRK .Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant2003;32:S57-9.">Craig 2003</a>; <a href="./references#CD013070-bbs2-0082" title="KreiselW , PotthoffK , BertzH , Schmitt-GraeffA , RufG , RasenackJ , et al.Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant2003;32(3):337-40.">Kreisel 2003</a>; <a href="./references#CD013070-bbs2-0098" title="OyamaY , CraigRM , TraynorAE , QuigleyK , StatkuteL , HalversonA , et al.Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology2005;128(3):552-63.">Oyama 2005</a>). The largest multicentre, randomised clinical trial of autologous HSCs in refractory CD was conducted from 2007 to 2011, with follow‐up through 2013 (<a href="./references#CD013070-bbs2-0074" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34.">Hawkey 2015</a>). The infusion of either autologous or allogeneic HSCs is associated with adverse events, with cardiovascular and pulmonary adverse events being common (<a href="./references#CD013070-bbs2-0118" title="VidulaN , VillaM , HelenowskiIB , MerchantM , JovanovicBD , MeagherR , et al.Adverse events during hematopoietic stem cell Infusion: analysis of the infusion product. Clinical Lymphoma, Myeloma &amp; Leukemia2015;15(11):e157-62.">Vidula 2015</a>). </p> <p>Mesenchymal stem (stromal); cells (MSCs) are multipotent cells that have immunomodulating capabilities to down‐regulate mucosal immune reactivity and promote tissue healing. MSCs can induce apoptosis (programmed cell death) of lymphocytes, thus, decreasing their proliferation in vitro. There are only a few studies reporting on the use of autologous (<a href="./references#CD013070-bbs2-0062" title="DuijvesteinM , VosAC , RoelofsH , WildenbergME , WendrichBB , VerspagetHW , et al.Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut2010;59(12):1662-9.">Duijvestein 2010</a>), or allogeneic (<a href="./references#CD013070-bbs2-0065" title="ForbesGM , SturmMJ , LeongRW , SparrowMP , SegarajasingamD , CumminsAG , et al.A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clinical Gastroenterology and Hepatology2014;12(1):64-71.">Forbes 2014</a>), bone marrow‐derived MSCs for luminal CD. In fistulising CD, local injection of MSCs may be beneficial for healing of the fistula (<a href="./references#CD013070-bbs2-0052" title="CiccocioppoR , BernardoME , SgarellaA , MaccarioR , AvanziniMA , UbezioC , et al.Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut2011;60(6):788-98.">Ciccocioppo 2011</a>; <a href="./references#CD013070-bbs2-0061" title="dela PortillaF , AlbaF , Garcia-OlmoD , HerreriasJM , GonzalezFX , GalindoA .Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. International Journal of Colorectal Disease2013;28(3):313-23.">de la Portilla 2013</a>; <a href="./references#CD013070-bbs2-0067" title="Garcia-OlmoD , Garcia-ArranzM , HerrerosD , PascualI , PeiroC , Rodriguez-MontesJA .A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Diseases of the Colon and Rectum2005;48(7):1416-23.">Garcia‐Olmo 2005</a>; <a href="./references#CD013070-bbs2-0068" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86.">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0066" title="García-ArranzM , HerrerosMD , González-GómezC , dela QuintanaP , GuadalajaraH , Georgiev-HristovT , et al.Treatment of Crohn's-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Translational Medicine2016;5(11):1441-6.">García‐Arranz 2016</a>; <a href="./references#CD013070-bbs2-0085" title="LeeWY , ParkKJ , ChoYB , YoonSN , SongKH , KimDS , et al.Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells (Dayton, Ohio)2013;31(11):2575-81. [PMID: 23404825]">Lee 2013</a>). </p> <p>The effect of stem cells on the treatment of CD might be due to their regenerative effect on local healing of fistulas and colitis. Mesenchymal stem cells are the commonest type of stem cells used in CD treatment, with the possibility of commercial availability and easier non‐hazardous preparation; with proper lab preparation and "Good manufacturing practice" (GMP). Limitations that might face this treatment are; the absence of dose standardisation, indeterminate concomitant medication "wash‐out" period, insufficient data about the effect of using allogenic versus autologous cells, high cost, and the ethical issues related to some sources of MSCs as the placenta and the umbilical cord (<a href="./references#CD013070-bbs2-0088" title="LightnerAL .The present state and future Direction of regenerative medicine for perianal Crohn's disease. Gastroenterology2019;156(8):2128-2130. e4.">Lightner 2019a</a>; <a href="./references#CD013070-bbs2-0089" title="LightnerAL , DuZ , PetersonTE , ShiA , LiM , RomeroAS , BehfarA .Commonly used immunosuppressives affect mesenchymal stem cell viability and function: should we rethinking clinical trial inclusion and exclusion criteria?Crohn's Colitis 3602019;1(3):1-8.">Lightner 2019b</a>). </p> <p>There is a concern about the safety of hematopoietic stem cells use to "reset the immune system" as the hazards during the conditioning phase could overshadow the benefits (<a href="./references#CD013070-bbs2-0080" title="Jauregui-AmezagaA , RoviraM , MarínP , SalasA , Pinó-DonnayS , FeuF , et al.Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. Gut2016;65(9):1456-62.">Jauregui‐Amezaga 2016</a>). </p> </section> <section id="CD013070-sec-0014"> <h3 class="title" id="CD013070-sec-0014">Why it is important to do this review</h3> <p>Patients with refractory CD suffer high morbidity and mortality. Controversy regarding the potential benefits and harms of stem cell transplant for patients with refractory CD still exists (<a href="./references#CD013070-bbs2-0063" title="DuranNE , HommesDW .Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology2016;9(4):533-47.">Duran 2016</a>; <a href="./references#CD013070-bbs2-0069" title="GomollónF , DignassA , AnneseV , TilgH , Van AsscheG , LindsayJO , et al.3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis2017;11(1):3-25.">Gomollón 2017</a>). This systematic review summarises the current evidence regarding the efficacy and safety of stem cell transplantation in refractory CD.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013070-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013070-sec-0015"></div> <p>The objective of this review is to assess the effects of stem cell transplantation compared to standard of care alone or with placebo on efficacy and safety outcomes in patients with refractory Crohn's disease (CD). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013070-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013070-sec-0016"></div> <section id="CD013070-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013070-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included all published, unpublished, and ongoing randomised controlled trials (RCTs) that assessed the efficacy and safety of stem cell transplantation compared to standard of care alone or with placebo used for refractory Crohn's disease. We included studies with parallel comparisons, either two or more groups comparing separate doses of the intervention, only if the control group was presented separately as one of the parallel groups. In the case of multi‐arm trials, we combined the intervention arms as one and compared it with the control arm (section 23.3.2 Handbook <a href="./references#CD013070-bbs2-0078" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane. Available from www.training.cochrane.org/handbook.. Chichester (UK): John Wiley &amp; Sons, 2021.">Higgins 2021</a>). This was done to avoid the repeated counting of the participants or unreasoned omission of relevant groups with the resulting over or underestimation of precision (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>). </p> <p>We also included cross‐over trials (<i>as indicated in the protocol)</i> (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), only if they had data available before the cross‐over phase.  Two ongoing trials (<a href="./references#CD013070-bbs2-0033" title="Mesenchymal stem cells for the treatment of Perianal Fistulizing Crohn's Disease (PFCD). NCT045196712020. ">NCT04519671</a>; <a href="./references#CD013070-bbs2-0035" title="Mesenchymal stem cells for the treatment of Rectovaginal Fistulas in participants with Crohn's disease (RVF). NCT045196972020. ">NCT04519697</a>) stated that they are cross‐over trials; we will include them in future analysis if the data before the cross‐over is presented in their final data. RCTs that contained patients complaining of different diseases causing perianal fistula (mixed population)(<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>), but stated clearly and separately their data concerning the Crohn's disease‐associated fistula patients were also included. We did not include non‐randomised or quasi‐randomised trials. </p> </section> <section id="CD013070-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included participants with refractory Crohn's disease (Patients who received previously one or more failed standard treatments) as defined by conventional clinical, radiological or endoscopic criteria. We did not restrict inclusion by age or gender. </p> </section> <section id="CD013070-sec-0020"> <h4 class="title">Types of interventions</h4> <p>Interventions that involved the administration of different types of stem cells were considered for inclusion. </p> <p>We included the following comparisons.</p> <p> <ol id="CD013070-list-0001"> <li> <p>Haematopoietic stem cells (HSCs) transplantation as compared with placebo or control receiving the standard of care. </p> </li> <li> <p>Mesenchymal stem cells (MSCs) transplantation as compared with placebo or control receiving the standard of care. </p> </li> <li> <p>Local MSCs injection as compared with placebo or control receiving the standard of care. </p> </li> </ol> </p> </section> <section id="CD013070-sec-0021"> <h4 class="title">Types of outcome measures</h4> <p>We extracted primary and secondary outcomes.</p> <section id="CD013070-sec-0022"> <h5 class="title">Primary outcomes</h5> <p>The primary outcomes included the following.</p> <p> <ol id="CD013070-list-0002"> <li> <p>Clinical remission, as defined by the original studies.</p> </li> <li> <p>Crohn's Disease Activity Index (CDAI) of &lt; 150),or a Pediatric Crohn’s Disease Activity Index (PCDAI) of &lt; 15 at weeks four to six (early), weeks 10 to 12 (middle), and weeks 15 or later (late) following initiation of therapy. But no paediatric population was present in all the included studies. </p> </li> <li> <p>Complete closure of the fistula as defined by original studies (e.g. complete closure of the fistula tract including internal and external openings without drainage or any sign of inflammation either detected; assessed clinically or by magnetic resonance imaging (MRI) or Perianal Disease Activity Index score (PDAI score)). </p> </li> </ol> </p> </section> <section id="CD013070-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included the following.</p> <p> <ol id="CD013070-list-0003"> <li> <p>Clinical improvement, as defined by the original studies.</p> </li> <li> <p>Endoscopic remission, as defined by the original studies e.g. Crohn's disease endoscopic index of severity (CDEIS), simple endoscopic score for Crohn's disease(SES‐CD), Rutgeerts' postoperative endoscopic index. </p> </li> <li> <p>Endoscopic improvement, as defined by the original studies.</p> </li> <li> <p>Adverse events (e.g. perianal abscess, bacterial gastroenteritis).</p> </li> <li> <p>Serious adverse events (e.g. sepsis, graft versus host disease).</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Quality of life as defined by the original studies e.g. Inflammatory Bowel Disease Questionnaire (IBDQ) or Short Form Health Survey(SF‐36), IBD‐Control 8, Crohn's Ulcerative Colitis Questionnaire‐8 (CUCQ‐8), or IMPACT III for pediatric patients. </p> </li> </ol> </p> </section> </section> </section> <section id="CD013070-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched electronic databases and trial registries. We also searched published reviews and meta‐analyses dealing with the topic in question for study inclusion. </p> <section id="CD013070-sec-0025"> <h4 class="title">Electronic searches</h4> <p>To identify relevant studies, we searched the following databases from inception to 19 March 2021 without imposing any language, publication year, or publication status restrictions. </p> <p> <ol id="CD013070-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (from inception, via Ovid Evidence‐Based Medicine Reviews Database (EBMR)) (<a href="./appendices#CD013070-sec-0097">Appendix 1</a>). </p> </li> <li> <p>MEDLINE (from 1946, via Ovid) (<a href="./appendices#CD013070-sec-0098">Appendix 2</a>):  </p> <ul id="CD013070-list-0005"> <li> <p>all from 1946 to 2021 March 19</p> </li> </ul> </li> <li> <p>Embase (from 1974, via Ovid) (<a href="./appendices#CD013070-sec-0099">Appendix 3</a>):  </p> <ul id="CD013070-list-0006"> <li> <p>Embase Classic+Embase 1947 to 2021 March 19</p> </li> <li> <p>Embase 1974 to 2021 March 19</p> </li> <li> <p>Embase 1974 to 2021 Week 11</p> </li> <li> <p>Embase 1980 to 2021 March 19</p> </li> <li> <p>Embase 1980 to 2021 Week 11</p> </li> <li> <p>Embase Classic 1947 to 1973</p> </li> </ul> </li> <li> <p>The Cochrane Gut Group Specialised Register, as a part of CENTRAL.</p> </li> </ol> </p> <p>The performed new search strategy was developed by a Cochrane Information Specialist in March 2021. </p> </section> <section id="CD013070-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We searched the following databases for ongoing trials.</p> <p> <ul id="CD013070-list-0007"> <li> <p>United States (US) National Institutes of Health Trials Registry (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>) (<a href="./appendices#CD013070-sec-0100">Appendix 4</a>). </p> </li> <li> <p>The World Health Organization (WHO) Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">apps.who.int/trialsearch/default.aspx</a>) (<a href="./appendices#CD013070-sec-0101">Appendix 5</a>). </p> </li> </ul> </p> <section id="CD013070-sec-0027"> <h5 class="title">Checking reference lists</h5> <p>We handsearched reference lists of all included primary studies and relevant review articles for additional studies. </p> </section> </section> </section> <section id="CD013070-sec-0028"> <h3 class="title" id="CD013070-sec-0028">Data collection and analysis</h3> <p>We used the standard methodological procedures as stated in the Cochrane Handbook in conducting and reporting this systematic review (<a href="./references#CD013070-bbs2-0077" title="HigginsJPT , LassersonT , ChandlerJ , ToveyD , ChurchillR .Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version 1.02,2016.">Higgins 2016</a>; <a href="./references#CD013070-bbs2-0078" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane. Available from www.training.cochrane.org/handbook.. Chichester (UK): John Wiley &amp; Sons, 2021.">Higgins 2021</a>). </p> <p>An expert Statistician (MEN) conducted the conversions done in data extraction and also helped in conducting the data analysis, both according to the Cochrane Handbook. The methods are mentioned in detail in (<a href="./appendices#CD013070-sec-0102">Appendix 6</a>). </p> <section id="CD013070-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We conducted a previous search in 2018, another separate updated search was conducted on 19 March 2021. Two review authors (SEN and SFA) independently reviewed the titles and abstracts of the studies identified from the literature search. The full texts were assessed by (SEN and SFA) for the final inclusion of studies. The screening of the titles, abstracts, and full texts was conducted by SEN and SFA using the <b>COVIDENCE Program</b> (<a href="./references#CD013070-bbs2-0040" title="BabineauJ .Product Review: Covidence (Systematic Review Software). Journal of the Canadian Health Libraries Association / Journal De l’Association Des bibliothèques De La Santé Du Canada2014;35(2):68-71. [DOI: https://doi.org/10.5596/c14-016]">Babineau 2014</a>) in the updated search of 19 March 2021.  </p> <p>In the current 19 March 2021 search, two review authors (SEN and SFA) screened the results of the database search of 639 records with two records added from manual search to the total number of 641 records. The two records added by the manual search were (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> and <a href="./references#CD013070-bbs2-0020" title="KnyazevO , KagramanovaA , LischinskayaA , KorneevaI , ZvyaglovaM , BabayanA , et al.Stem cell therapy for perianal Crohn’s disease. Proceedings of the Latvian Academy of Sciences (Section B)2020;74(2 (725)):68–74. ">Knyazev 2020</a>). Then 125 duplicates were removed. Both SEN and SFA screened the titles and abstracts of the remaining 516 reports with excluding 451 reports. Furthermore, the two review authors screened the remaining 65 full‐text reports for final inclusion, and a total number of 18 studies were included (9 ongoing trials, seven included RCTs, two abstracts of studies were added to studies awaiting classification (<a href="#CD013070-fig-0001">Figure 1</a>). Any discrepancies during the inclusion phase were resolved through consensus between the two authors (SEN and SFA). Then both authors added the updated extracted data in a data word sheet formed previously. SEN conducted the data analysis using RevMan Web (<a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>) and formulated the summary of findings (SoF) table using (<a href="./references#CD013070-bbs2-0070" title="GRADEpro GDT.Version accessed 3 July 2018. Hamilton (ON): GRADE Working Group, McMaster University, 2015.">GRADEpro GDT</a>) through the RevaMan Web‐GRADEPro integration. We created a study flow diagram using the <b>RevMan web software (</b><a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>); to map out the number of records identified, included, awaiting classification, ongoing, and excluded according to PRISMA guidelines, as shown in (<a href="#CD013070-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013070-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="The flow diagram of the new search strategy (updated in 20 March 2021) Using COVIDENCE for screening (COVIDENCE Program)" data-id="CD013070-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The flow diagram of the new search strategy (updated in 20 March 2021) Using COVIDENCE for screening (COVIDENCE Program) </p> </div> </div> </div> <p>We planned to include trials presented as abstracts if the full data was present after contacting the authors, or if the primary outcome is present otherwise the study was excluded. </p> <p>We previously tried unsuccessfully to contact the authors of the two studies awaiting classification (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a>; <a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>) and again contacted them in October 2021, and we are waiting for their reply. However, we found the data in the abstracts insufficient to include in quantitative or qualitative analysis, hence they were moved the two studies to the (<a href="./references#CD013070-bbs1-0003" title="">Studies awaiting classification</a>) section. </p> </section> <section id="CD013070-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We designed a data extraction sheet and extracted data in our previous 2018 search.</p> <p>In our current 19 March 2021 search, review authors SEN and SFA independently extracted the data from the included studies to our previously designed data extraction form. Any discrepancies were resolved by a consensus of the two authors (SEN and SFA). Data are presented in(<a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>). </p> <p>We entered data into Review Manager software (<a href="./references#CD013070-bbs2-0104" title="Review Manager (RevMan).Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). After October 2020 we used RevMan Web (<a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> <p><b>Extracted data included the following items: (as presented in </b><a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a><b> and additional </b><a href="#CD013070-tbl-0002">Table 1</a>). </p> <div class="table" id="CD013070-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data Extracted from the included studies:</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CCC of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In ALL study</p> <p>43.33, SD 9.9</p> <p>I: mean 42.64, SD 10.93</p> <p>P: 43.99, SD 8.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age: 38<br/>Group 1:<br/>Mean: 40.4 (27‐54)<br/>Group 2:<br/>Mean: 40.8 (37‐47)<br/>Group 3:<br/>Mean: 33.4 (21‐48)<br/>Placebo:<br/>Mean: 37.3 (27‐49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unit: mean 35.3 SD 14</p> <p>4 units: mean 36.2 SD 11.6</p> <p>Placebo: mean 36.5 SD7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: mean 39.0 (13.1)</p> <p>P: mean 37.6 (13.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;18y‐70 years</p> <p>I:34.3 (21‐44)</p> <p>P: 32.7(20‐41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:<br/>Median: 34.1<br/>IQR: (26.1‐41.2)<br/>P:<br/>Median: 30.6<br/>IQR:(24.0‐37.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range from; 12‐51</p> <p>28.86 ± 10.13</p> <p>I: 24.4 ± 5.0<br/>C: 24.9 ± 5.4 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all study 24/25</p> <p>M/F</p> <p>I: 10/14</p> <p>P: 14/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male in 4 groups:</p> <p>4/5</p> <p>4/5</p> <p>1/5</p> <p>3/6</p> <p>M/F: 12/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unit:53.3% M/F:8/7</p> <p>4 units:33.3 % 5/10</p> <p>placebo:43.8% 7/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 60/47</p> <p>P: 56/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:</p> <p>24/17</p> <p>P:</p> <p>26/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women:</p> <p>I: 13/23</p> <p>P: 11/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 female</p> <p>21 male</p> <p>(M/F)<br/>Intervention: 11/0<br/>Control: 10/1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease duration in years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In years in 4 groups</p> <p>I: 7.6 (5‐11)</p> <p>II: 16.8 (5‐28)</p> <p>III: 13.2 (2‐23)</p> <p>Placebo: 6.8 (1‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>I unit:18.5 yrs SD 13.8</p> <p>4 units:10.4 yrs SD 10.7</p> <p>placebo: 16.2 yrs SD9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 12.1 (10.0)</p> <p>P: 11.3 (8.9) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7 (2‐15)<br/>C: 8 (3‐14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 14.9 y</p> <p>P: 11.2 y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease location</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rectovaginal fistula = 8/49<br/>I= 4, P= 4<br/>Suprasphincteric fistulous tract= 30/49<br/>I= 14, P= 16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perianal</p> <p>Group 1:<br/>L1= 1, L2 =3, L3=1 </p> <p>Group 2:<br/>L1= 1, L2=2,L3= 2<br/>Group 3:<br/>L1=2,L2=1,L3=2<br/>Placebo:<br/>L1=1,L2=2,L3=2, L3+L4=1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perianal</p> <p>High inter‐sphincteric, trans‐sphincteric, extra‐sphincteric or supra‐sphincteric.</p> <p>(?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I/C</p> <p>Ileal: 14/17</p> <p>Colonic:18/14</p> <p>Ileocolonic:9/10</p> <p>Isolated upper:6/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention:<br/>Ileum (L1) 1 (9.1%) Colon (L2) 4 (36.4%) Ileocolon (L3) 6 (54.6%) </p> <p>Upper GI (L4) 0 (0.0%)<br/>Control:<br/>Ileum (L1): 1 (9.1%) </p> <p>Colon (L2): 3 (27.3%)</p> <p>Ileocolon (L3): 7 (63.6%)</p> <p>Upper GI (L4) 0 (0.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Previous and concomitant medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at least one complete</p> <p>course of antibiotics with a seton placement or conventional</p> <p>surgery (advancement flap or fistulectomy), at</p> <p>least one complete induction course of infliximab, unless</p> <p>anti‐TNF‐α treatment was contraindicated</p> <p><b>Concomitant</b>: any except infliximab, tacrolimus, or cyclosporine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mesalamine, steroids, anti TNF, immunosuppressives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminosalicylates‐corticosteroids‐immunomodulators‐biologics (at least 3m before study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>concomitant but refractory to immunomodulatory and anti‐TNF and antibiotics at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids for the last 6 months and as background treatment</p> <p>Anticoagulation prior to treatment (2,500 IU of low‐molecular‐weight heparin )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I/P</p> <p>Prior drugs:</p> <p>Azathioprine/6MP:22/22</p> <p>Methotrexate:19/18</p> <p>Anti TNF:23/22</p> <p>Other:10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During the study, all patients received</p> <p>aminosalicylic acid (Mesalazine) and probiotic treatment.</p> <p>One patient in the observation group and three patients in</p> <p>the control group received immunomodulator treatment.</p> <p>One patient in each group was given antibiotics.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Previous bowel surgeries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (adv flap or fistulectomy)</p> <p>Previous fistula surgery: 39/49<br/>I= 17, P= 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:12</p> <p>P:9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 2/23</p> <p>P: 2/22</p> <p>Ileostomy:</p> <p>I: 4/23</p> <p>P: 4/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This clinical trial has been sponsored by Cellerix S.L.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This work was supported by the DigestScience Foundation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the study is funded by Celularity Incorporated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study was funded by TiGenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study was sponsored by<br/>the European Group for Blood and Marrow<br/>Transplantation (EBMT) Autoimmune Diseases<br/>Working Party and the European Crohn and Colitis<br/>Organisation (ECCO). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This work was funded by Key Medical Science and Technology Development</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data here are not mentioned in the characteristics of the studies.</p> </div> </div> <p> <ol id="CD013070-list-0008"> <li> <p>Characteristics of patients: age, sex, disease duration, disease location, type of Crohn’s disease activity index used. </p> </li> <li> <p>The total number of patients in each study and in each group.</p> </li> <li> <p>Previous and concomitant medications used.</p> </li> <li> <p>Outcomes: clinical remission, quality of life, mortality, adverse effects.</p> </li> <li> <p>Type of intervention: HSCs or MSCs, etc.</p> </li> <li> <p>Type of stem cells used: autologous or allogeneic.</p> </li> <li> <p>Route of administration: systemic or local.</p> </li> <li> <p>Mode and source of collection of the cells: direct marrow biopsy, cell mobilisation from the marrow, somatic cells reprogrammed, umbilical cord, adipose tissue. </p> </li> <li> <p>Type of reconditioning used in cell collection if present.</p> </li> <li> <p>Disease behaviour (inflammatory, fibro stenosing, penetrating).</p> </li> </ol> </p> <p><b>We added the following to the previous items.</b> </p> <p> <ul id="CD013070-list-0009"> <li> <p>The dosage of the injected cells either local or systemic injection.</p> </li> <li> <p>The selected endpoint of the primary study.</p> </li> <li> <p>The number of centres in the study.</p> </li> <li> <p>Primary country conducting the study.</p> </li> <li> <p>The comparative intervention used (placebo or other intervention).</p> </li> </ul> </p> <p><b>We added additional data extraction form for the included trials retrieved from the search strategy to assess their status and further characteristics(</b><a href="./references#CD013070-sec-0124" title="">Characteristics of ongoing studies</a>). </p> <p> <ol id="CD013070-list-0010"> <li> <p>Whether published or not.</p> </li> <li> <p>The type of stem cell therapy (SCT) they use.</p> </li> <li> <p>The phase of the trial.</p> </li> <li> <p>Status of the trial (ongoing, finished, or withdrawn).</p> </li> <li> <p>Arms of the study.</p> </li> <li> <p>Local or systemic injection.</p> </li> <li> <p>Start and end dates of the trial.</p> </li> </ol> </p> </section> <section id="CD013070-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SEN and SFA) independently assessed the risk of bias for each study using the Cochrane risk of bias tool (<a href="./references#CD013070-bbs2-0076" title="HigginsJPT , Altman DG (editors).Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Detailed methods for the risk of bias assessment are shown in <a href="./appendices#CD013070-sec-0103">Appendix 7</a>. </p> <p>We assessed the following items.</p> <p> <ol id="CD013070-list-0011"> <li> <p>Random sequence generation (checking for possible selection bias).</p> </li> <li> <p>Allocation concealment (checking for possible selection bias).</p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias).</p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias).</p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). </p> </li> <li> <p>Selective reporting (checking for reporting bias).</p> </li> <li> <p>Other biases (checking for bias due to problems not covered by items above): e.g. funding issues, baseline characteristics of the patients across groups, type of stem cells used (single versus multiple donors), etc. </p> </li> </ol> </p> <p>For each item, we made explicit judgments about the high, low, or unclear risk of bias. Overall, we made explicit judgments about whether studies were at (high, low, or some concerns) risk of bias. Two review authors (SEN and SFA) independently assessed the risk of bias using the ROB2 domains assessment format with guidance from <i>version 6.2 of the Cochrane Handbook</i>(<a href="./references#CD013070-bbs2-0078" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane. Available from www.training.cochrane.org/handbook.. Chichester (UK): John Wiley &amp; Sons, 2021.">Higgins 2021</a>). For each item, we asked signalling questions to reach the judgment. Reasons for each judgment are written in detail in the <a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>. When disagreement of the judgment occurred, it was resolved by a consensus between the two authors. </p> <p>With reference to (1) to (7) above, we assessed the likely magnitude and direction of the bias and whether we consider it was likely to impact the findings. We planned to explore the impact of the level of bias by conducting sensitivity analysis (see <a href="#CD013070-sec-0039">Sensitivity analysis</a>). </p> </section> <section id="CD013070-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>All data were analysed on an intention‐to‐treat (ITT) basis using Review Manager Web (<a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). We calculated the risk ratio (RR) and corresponding 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. In some analyses with differences in the presentation of the same outcome, we used standardised mean difference (SMD). </p> </section> <section id="CD013070-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>When studies reported multiple observations for the same outcome, we combined outcomes for fixed intervals of follow‐up (e.g. clinical remission at eight weeks).  </p> <p>We planned to include cross‐over trials if data were available from the first phase of the study (i.e. before cross‐over). Only one study (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) was a cross‐over trial, where participants in the control group underwent the intervention after one year. We only included the results before the cross‐over as stated in the protocol.  </p> <p>In <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>, the studied population was heterogeneous, but the Crohn's disease group was documented separately in the results and methods section, so we could extract the data of the Crohn's disease‐only population. </p> <p>Separate comparisons were planned to be conducted for stem cell therapy versus standard therapy alone versus standard therapy with placebo but the number of studies using placebo was small. If studies allocated participants to more than one stem cell treatment arm, these studies were pooled for the primary analysis as (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>). </p> </section> <section id="CD013070-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>The analysis of the two primary outcomes was carried out using intention‐to‐treat (ITT) analyses. We planned to contact the trialists to request missing data, or to ascertain the reason for data loss, but we did not need to because most of the included studies provided online supplementary detailed data which we used. We only tried to contact the trialists with the unclear methodology of their trials, but got no response and a consensus was formed to exclude those studies due to unclear methodology (<a href="./references#CD013070-bbs2-0017" title="KagramanovaA , Knyazev, O, KonoplyannikovA .P-068 The combined of mesenchymal stem cells and anticytokine therapy reduces the recurrence rate of Crohn's disease. Inflammatory Bowel Diseases2016;22(suppl-1):S31-S31. ">Kagramanova 2016</a>; <a href="./references#CD013070-bbs2-0018" title="KnyazevOV , IvanovichPA , GeorgievichKA , KagramanovaKA .Safety of mesenchymal stem cells therapy in patients with inflammatorybowel diseases a 5 year follow-up. Journal of Biotechnology &amp; Biomaterials2015;5(3):1-5. ">Knyazev 2015</a>; <a href="./references#CD013070-bbs2-0021" title="LazebnikL , KnyazevO , KonoplyannikovA , ParfenovA , RuchkinaI , RogozinaV , et al.T1751 Transplantation of allogenic mesenchimal stem cells is a new method of biological therapy of Crohn's disease. Gastroenterology2010;138(5):S-571. ">Lazebnik 2010</a>) whether randomised trials or cohort studies. </p> <p>Although attrition was low in all studies, all the studies with missing data had supplementary material online in addition to the published manuscripts (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>, and <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) providing a detailed explanation and how missing data were dealt with. </p> <p>Otherwise, missing dichotomous data were planned to be assumed as treatment failure. The impact of this assumption on the effect estimate was planned to be assessed by performing sensitivity analyses where appropriate, but the number of studies was too low to conduct such analysis. We planned to conduct an available case analysis for continuous outcomes with missing data. </p> </section> <section id="CD013070-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity for each pooled analysis using the Tau<sup>2</sup>, I<sup>2</sup> and Chi<sup>2</sup> statistics. We regarded heterogeneity as substantial if an I<sup>2</sup> was greater than 50% and either the Tau<sup>2</sup> was greater than 1, or the P value for the Chi<sup>2</sup> test was statistically significant (i.e. less than 0.10). </p> <p>We assessed heterogeneity using the Chi²test (P &lt; 0.10, significant heterogeneity) and I² statistic (&gt; 50%, substantial heterogeneity) using a random‐effects model along with visual inspection of forest plots. Following the guidance of the Cochrane Handbook (<a href="./references#CD013070-bbs2-0078" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane. Available from www.training.cochrane.org/handbook.. Chichester (UK): John Wiley &amp; Sons, 2021.">Higgins 2021</a>), we defined I² = 0% to 30% as not important heterogeneity, 31% to 50% as moderate heterogeneity, 51% to 90% as substantial heterogeneity, and 91% to 00% as considerable heterogeneity. When substantial or considerable heterogeneity was found, possible explanations were investigated by subgroup and sensitivity analyses to test the robustness of the overall results. </p> </section> <section id="CD013070-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to include all the eligible studies either published or unpublished. In the case of unpublished trials and abstract‐only published studies, we contacted the authors for further data and classified them as studies "awaiting classification" until full data were available for quantitative and qualitative assessment. In case of unfinished trials, we classified them as "ongoing trials".  We planned to investigate the reporting bias in the form of publication bias of all the reported studies (published and unpublished) by drawing a funnel plot and visualising any asymmetry, but as the number of the relevant studies was small (only seven published and two unpublished studies as compared to the minimum required number for assessment i.e. 10 studies) we could not assess the reporting publication bias. </p> </section> <section id="CD013070-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD013070-bbs2-0104" title="Review Manager (RevMan).Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and RevManweb (<a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>) after 2020. We combined data from individual trials for meta‐analysis when the interventions, patient groups, and outcomes were sufficiently similar (as determined by consensus). </p> <p>When we suspected a high degree of clinical or baseline heterogeneity supported by a high degree of statistical heterogeneity as detected by (I<sup>2</sup> ≥ 75%), we planned not to pool data for meta‐analysis, and we did that with two outcomes where their I<sup>2</sup> was &gt;75%; endoscopy scores and CDAI after 24 weeks. </p> <p>As for the mortality outcome, we found that only two patients died from two studies, and due to the high number of zeros in the other studies<b>,</b> we performed Peto Odds ratio (OR) as recommended by Dr. Burch. </p> </section> <section id="CD013070-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses if we identified substantial heterogeneity (I<sup>2</sup> statistic ≥ 50% or P for heterogeneity &lt; 0.1) was detected. </p> <p> <ol id="CD013070-list-0012"> <li> <p>Autologous versus allogeneic stem cells.</p> </li> <li> <p>High‐dose versus low‐dose stem cells.</p> </li> <li> <p>Paediatric versus adult participants.</p> </li> <li> <p>Male versus female participants.</p> </li> <li> <p>Treatment after recurrence versus treatment‐naive participants.</p> </li> </ol> </p> <p>However, with only seven studies included in the review, there were insufficient data to perform these analyses. Consequently, results of included studies were reported only as narrative results as shown in <a href="#CD013070-sec-0045">Included studies</a>. </p> </section> <section id="CD013070-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted the following sensitivity analyses for the primary outcomes.</p> <p> <ul id="CD013070-list-0013"> <li> <p>Repeated analyses using a random‐effects model where we identified substantial heterogeneity.</p> </li> <li> <p>Restricted analyses to trials with a low risk of bias.</p> </li> </ul> </p> </section> <section id="CD013070-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD013070-sec-0041"> <h5 class="title">GRADE and summary of findings table</h5> <p>We used the GRADE approach (<a href="./references#CD013070-bbs2-0113" title="SchünemannHJ .GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice [GRADE: Von der Evidenz zur Empfehlung. Beschreibung des Systems und Losungsbeitrag zur Ubertragbarkeit von Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen2009;103(6):391-400.">Schünemann 2009</a>), to create a summary of findings table for the following main outcomes (<a href="./full#CD013070-tbl-0001">summary of findings Table 1</a>). </p> <p> <ol id="CD013070-list-0014"> <li> <p>Clinical remission.</p> </li> <li> <p>Clinical improvement in the form of CDAI &lt;150 achievement after 24 weeks.</p> </li> <li> <p>Fistula closure (short and long term)</p> </li> <li> <p>Total adverse events.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ol> </p> <p>We used <a href="./references#CD013070-bbs2-0070" title="GRADEpro GDT.Version accessed 3 July 2018. Hamilton (ON): GRADE Working Group, McMaster University, 2015.">GRADEpro GDT</a> to import data from Review Manager Web (<a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>) through "<b><i>integration</i> </b>" in order to create the summary of findings table. A summary of the intervention effect and a measure of certainty for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. Evidence from randomised trials starts as 'high certainty', the evidence is downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on the assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates and potential publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013070-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013070-sec-0042"></div> <section id="CD013070-sec-0043"> <h3 class="title">Description of studies</h3> <p>For a full description of the included studies kindly see <a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>, for secluded studies <a href="./references#CD013070-sec-0122" title="">Characteristics of excluded studies</a>, and for ongoing trials full description please see <a href="./references#CD013070-sec-0124" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013070-sec-0044"> <h4 class="title">Results of the search</h4> <p>We conducted the first search in 2018 and conducted the updated search on 19 March 2021. We retrieved 639 records; 360 records from (CENTRAL <a href="./appendices#CD013070-sec-0097">Appendix 1</a> and MEDLINE <a href="./appendices#CD013070-sec-0098">Appendix 2</a>), and 279 records from (Embase <a href="./appendices#CD013070-sec-0099">Appendix 3</a>). We added two records through our manual search of published studies on the topic (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> and <a href="./references#CD013070-bbs2-0020" title="KnyazevO , KagramanovaA , LischinskayaA , KorneevaI , ZvyaglovaM , BabayanA , et al.Stem cell therapy for perianal Crohn’s disease. Proceedings of the Latvian Academy of Sciences (Section B)2020;74(2 (725)):68–74. ">Knyazev 2020</a>). The total number of studies retrieved was 641 records. </p> <p>Two review authors (SEN and SFA) screened the results of the database search, 125 duplicates were removed by COVIDENCE program (<a href="./references#CD013070-bbs2-0040" title="BabineauJ .Product Review: Covidence (Systematic Review Software). Journal of the Canadian Health Libraries Association / Journal De l’Association Des bibliothèques De La Santé Du Canada2014;35(2):68-71. [DOI: https://doi.org/10.5596/c14-016]">Babineau 2014</a>). Both SEN and SFA screened the titles and abstracts of the remaining 516 reports. We excluded 451 reports. The two review authors screened the remaining 65 full‐text reports for final inclusion, and 19 reports were excluded for the reasons mentioned in (<a href="#CD013070-fig-0001">Figure 1</a>). We added a specific detailed description and reasons for the exclusion of the excluded studies in the <a href="./references#CD013070-sec-0122" title="">Characteristics of excluded studies</a> section.  </p> <p>Duplicate reports of the included studies and their follow‐up were 28 publications. We included the 28 reports of the seven included RCTs (14 follow‐up reports and 14 duplicate publications), they were in the form of, republication of the same data, trial registries of the same study in different databases, protocol publication, or follow‐up data publication. So we screened the reports for any relevant new data and added them to the datasheet of the originally included studies (the 7 RCTs). This included the long‐term follow‐up and mortality data from those reports to our final analysis and quality of evidence assessment. The follow‐up report for <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> was <a href="./references#CD013070-bbs2-0099" title="PanésJ , García-OlmoD , VanAG , ColombelJF , ReinischW , BaumgartDC , et al.Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology2018;154(5):1334-1342.e4.">Panés 2018</a>, the follow‐up report for <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> was <a href="./references#CD013070-bbs2-0071" title="GuadalajaraH , HerrerosD , De-La-QuintanaP , TrebolJ , Garcia-ArranzM , Garcia-OlmoD .Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. International Journal of Colorectal Disease2012;27(5):595-600.">Guadalajara 2012</a>, and the follow‐up report for <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> was <a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>. </p> <p>A total number of 18 studies were finally included for qualitative analysis (two abstracts, nine ongoing trials, and seven RCTs). Any discrepancies were resolved through a consensus between the authors. The identified 18 studies for inclusion in the review were nine studies of ongoing trials(<a href="./references#CD013070-bbs2-0029" title="A clinical research study of an investigational new drug to treat perianal fistulas in patients with Crohn’s disease (CD). EU Clinical Trials Register. WexnerS , SandbornW , PanesJ , GilaberteI , GulatiP , ZhangB , et al.Design of a phase III, double-blind, randomized trial to evaluate the safety and efficacy of allogeneic stem cells (Darvadstrocel) for the treatment of complex perianal fistula(S) in patients with Crohn's disease (ADMIRE-CD II trial).. Diseases of the Colon and Rectum2020;63(6):e300. ">EUCTR2017‐000725‐12‐CZ</a>; <a href="./references#CD013070-bbs2-0030" title="A randomised controlled trial to assess the safety and effectiveness of stem cell transplantation using a reduced intensity regimen in patients with treatment resistant Crohn’s disease. ISRCTN registry. SnowdenJA , HawkeyC , HindD , SwabyL , MellorK , Emsley R et al,  Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators, European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology2019;19(1):82. ">ISRCTN17160440</a>; <a href="./references#CD013070-bbs2-0031" title="Evaluation of PROCHYMAL® adult human stem cells for treatment-resistant moderate-to-severe Crohn's disease. ClinicalTrials.gov. ">NCT00482092</a>; <a href="./references#CD013070-bbs2-0032" title="Evaluation of local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN's fistulas (ADICROHN2). NCT040105262019. ">NCT04010526</a>; <a href="./references#CD013070-bbs2-0033" title="Mesenchymal stem cells for the treatment of Perianal Fistulizing Crohn's Disease (PFCD). NCT045196712020. ">NCT04519671</a>; <a href="./references#CD013070-bbs2-0034" title="Study of mesenchymal Stem cells for the treatment of Ileal Pouch Fistula's in participants with Crohn's disease (IPAAF). NCT045196842020. ">NCT04519684</a>; <a href="./references#CD013070-bbs2-0035" title="Mesenchymal stem cells for the treatment of Rectovaginal Fistulas in participants with Crohn's disease (RVF). NCT045196972020. ">NCT04519697</a>; <a href="./references#CD013070-bbs2-0036" title="Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's ColitisOfficial title: A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis. Ongoing study. November 4, 2020. Contact author for more information.">NCT04548583</a>; <a href="./references#CD013070-bbs2-0037" title="Clinical study to evaluate efficacy and safety of ASC and fibringlue or fibringlue in patients with Crohn's fistula. NCT046124652020. ">NCT04612465</a>), and seven RCTs <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) for the final quantitative meta‐analysis. We found two studies (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a> and <a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>) presented as abstract‐only data which we moved to <a href="./references#CD013070-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> <section id="CD013070-sec-0045"> <h4 class="title">Included studies</h4> <p>We ultimately included seven RCTs for meta‐analysis  <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>;  <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>;  <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) for the final qualitative and quantitative analysis with their secondary reports and online supplements assessed for further data. All data are shown in detail in the <a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a> section. We found multiple reports of the same study for (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). We included the long‐term follow‐up data from these records and mentioned the relevant references in the results.  </p> <p>Two of the included studies are awaiting classification (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a>; <a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>), both were presented with an abstract‐only publication, without enough data to assess in the current review. (<a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>) is a double‐blinded RCT with a subsequent compassionate open‐label trial on six patients (in the intervention group) with ileocolitis and intestinal CD. The patients were given four doses of remestemcel‐L (a commercial type of mesenchymal stem cell prepared from healthy young adults' bone marrow aspirate). The infused doses ranged from 0 to 400 million cells per dose, four subsequent infusions were given over the duration of several months. The study reported five of the six patients having a clinical response, with four of the six patients having improved CDAI &gt;100 points and no reported adverse events. (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a>) is a single‐centre phase II open‐label RCT using autologous expanded bone marrow‐derived mesenchymal stem cells (axBM‐MSC), conducted on 26 patients. The routes of injection were the mesenteric arteries (superior and inferior), through colonic endovascular catheterization. They reported symptomatic improvement and lowering of the CDAI score in the intervention group as compared to the control group. </p> <section id="CD013070-sec-0046"> <h5 class="title">1‐Study design, setting, and duration</h5> <section id="CD013070-sec-0047"> <h6 class="title">1.1 Phases of the included trials</h6> <p>Two of the trials were phase III studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; and <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) while five were phase I‐II studies (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> <p>Two studies were dose‐escalation studies with a placebo arm; (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) included three arms; one placebo and three intervention groups with different stem cell doses, and (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) included two arms of intervention and one in placebo. The other five studies (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> ; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) consisted of two arms only one intervention and one control or placebo. </p> </section> <section id="CD013070-sec-0048"> <h6 class="title">1.2 Study duration and follow‐up period</h6> <p>The study duration ranged from one year to four years in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) with a follow‐up duration period ranging from one to two years. </p> </section> <section id="CD013070-sec-0049"> <h6 class="title">1.3 The countries and the number of centres included in the trials</h6> <p>Four of the studies were multicentre trials (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), while three (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) were uni‐centre trials one in the Netherlands and two in China, respectively. The multicentre trials were also multinational trials in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). Panes contained the largest number of centres with 49. Most of the studies were carried out in Europe with one in the USA (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) and one in China (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>), also (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) included Israel in their multinational European trial. </p> </section> </section> <section id="CD013070-sec-0050"> <h5 class="title">2‐ Participants</h5> <p>We included seven RCTs. The total number of participants was 442 with 234 in the stem cell group and 208 in the placebo or control groups, with around 50% of the participants  included in one multicentre RCT (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). Studies were conducted in the UK, China, Spain, the Netherlands, and the USA. </p> <section id="CD013070-sec-0051"> <h6 class="title">2.1 Treatment after recurrence versus treatment‐naive participants</h6> <p>All participants were refractory to the primary medical treatment and no treatment‐naive patients were recruited. The inclusion criteria ranged from moderate to severe cases of Crohn's disease either luminal or fistulising disease, no patients with mild disease, or already on remission in both categories were included. </p> <p>All participants (both intervention and control groups) received concomitant therapy according to the study protocols as stated in details in (additional <a href="#CD013070-tbl-0002">Table 1</a>). </p> </section> <section id="CD013070-sec-0052"> <h6 class="title">2.2 The age of the participants:</h6> <p>All the studies excluded pregnant women. Only one study included children (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), where the age of the included participants ranged from 12 to 51 years old. In the rest of the studies; the minimum age for inclusion was 18 years old and was stated clearly in the studies. The (Interquartile range (IQR) and median) or (mean and standard deviation SD) of individual studies are shown in (Additional <a href="#CD013070-tbl-0002">Table 1</a>). Mean and median ranged from (30 to 44) years old i.e. around 31 years old. Only three of the studies set a limit on the maximum age for the inclusion of the participants; in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>), it was 75 years old and in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), it was 50 years old. </p> </section> <section id="CD013070-sec-0053"> <h6 class="title">2.3 The gender of the participants</h6> <p>From (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>), we included only the subgroup of 14 people with Crohn's disease; their gender distribution was not reported separately (total numbers 24 males and 25 females). Also, in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) there was an open Phase Ib non‐randomised one arm trial on four participants and Phase IIa trial on 46 participants; we only included the latter group. The rest of the studies with data on the number of male/female participants included a total number of 428 patients (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) with 240 males (56.07%) and 188 females (43.93%). </p> <p>There was no difference between the control and intervention groups regarding gender. The intervention group included 127 males (55.95%) and 100 females (44.05%), while the control/placebo group included 114 males (56.44%) and 88 females (43.56%). </p> </section> </section> <section id="CD013070-sec-0054"> <h5 class="title">3‐ Interventions</h5> <section id="CD013070-sec-0055"> <h6 class="title">3.1 Type of control used in the trials</h6> <p>The placebo in the local injection was saline only as in (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) or a combination of saline and albumin infusion without any cells in (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>). Unfortunately in (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), masking of the treatment was not achieved because the consistency of the stem cell suspension was apparently different from the saline solution. </p> <p>The fibrin‐glue in (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>) was used as a background treatment for both the intervention and the control groups. </p> <p>As for systemic infusion, the placebo group received a "vehicle control without any cells" in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>). </p> <p>While (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) did not state any placebo taken with the standard background treatment. Participants in the control group of <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a> received SCT with a delay of one year as compared to the intervention group (cross‐over trial). </p> </section> <section id="CD013070-sec-0056"> <h6 class="title">3.2 Autologous versus allogenic</h6> <p>The intervention was autologous stem cells in three trials; in the study of (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>); it was extracted from bone marrow stem cells and in both <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>,  the cells were extracted from adipose tissue through liposuction.  The stem cells used were allogeneic in four trials (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>). The used cells were commercially available (cenplacel‐L)‐ Human placenta‐derived cells (PDA‐001) in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> ) from placental tissues, in (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) Allogeneic, expanded, adipose‐derived stem cells (Cx601) cells‐ commercial cells through Human lipo aspirate from donor liposuction. While prepared allogeneic were from the umbilical cord of a newborn (Expanded Umbilical Cord Mesenchymal Stem Cells (UC‐MSCs)) in (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>), and from five different donors of bone marrow aspirate in(<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) where each patient received their SCs doses from a single donor. </p> <p>We identified no direct comparisons of autologous versus allogeneic stem cells and had insufficient data to explore this via subgroup analyses. </p> </section> <section id="CD013070-sec-0057"> <h6 class="title">3.3 The route of administration</h6> <p>The route of administration for three studies was systemic infusion (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>), while four received a local injection into the fistula (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> </section> <section id="CD013070-sec-0058"> <h6 class="title">3.4 The doses of the stem cells</h6> <p>The doses varied among studies; (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>) started with 2 million cells if no healing at eight weeks another dose of 4 million cells was given. </p> <p>In (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>); Group I; 10 million, Group II; 30 million, and Group III; 90 million. The response according to the dose varied. The change in the PDAI score decreased from 4.4 to 1.8 in the first group after 24 weeks, while the decline in the second group was most apparent on week 12. Oddly enough there was no decline in the highest dose group of 90 million, which may indicate that a moderate dose of stem cells could be the most appropriate for local injection, but the number of participants was very small (five in each of the three intervention arms). </p> <p>On the other hand, (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) had two arms of intervention in comparison to the placebo arm. Group I received 150 million cells (1 unit) and Group II received 600 million cells (4 units) and the dose was repeated after one week. The clinical response at four and six weeks; defined as the drop of CDAI by &gt; or = 100 points and/or 25% decline. This was achieved in both arms of the intervention group regardless of the dose used in (10/28) patients ie 36% as compared to the placebo group where 0% achieved clinical remission P value = 0.026, but clinical remission after four and six weeks was achieved in (4/28) patients i.e. 14% in the intervention group versus 0% in the placebo group withP value = 0.3. </p> <p>In (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), the patients received 120 million cells in a single injection, while in (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>) the patients received 1.6 million cells/ kg body weight once weekly with a total of four doses. In (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) a minimum dose of 3 million cells/kg on day 7. </p> <p>In (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) each fistula was injected with a different dose according to its diameter and length (&lt; 1 cm injected with 1 mL, 1‐2 cm injected with 2 mL). The suspension contained 5 million cells/ml of Adipose‐derived stem cell (ADSC). Multiple injections were performed in all quadrants of the fistula. </p> </section> <section id="CD013070-sec-0059"> <h6 class="title">3.5 The type of stem cells</h6> <p>Different studies used different types of stem cells; adipose tissue‐derived stem cells (a type of mesenchymal stem cells) in (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), mesenchymal stem cells in (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>), placental‐derived mesenchymal‐like stem cells (PDA‐001) in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>), and haematopoietic stem cells CD34+ in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>). </p> </section> <section id="CD013070-sec-0060"> <h6 class="title">3.6 Methods of preparation</h6> <p>Methods varied across the studies due to the different types of cells used. Conditioning was only used with <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>. </p> </section> </section> <section id="CD013070-sec-0061"> <h5 class="title">4‐ Results of Sensitivity Analysis</h5> <p>We carried out sensitivity analysis for the all the primary outcomes as shown in (<a href="./appendices#CD013070-sec-0111">Appendix 8</a>); clinical remission, CDAI &lt; 24 weeks, fistula closure short term and long term, but we found no differences when using random‐effects versus fixed‐effect models. In addition, our conclusions remained unchanged when excluding high and unclear risk studies. This could be attributed to the weight of the study (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>)which has the largest population studied, with more than 50% of the patients, and also has a low risk of bias. </p> <p>First, for clinical remission we found that there was a positive effect of the intervention as opposed to the control; risk ratio (RR) was 1.88, 95% confidence interval (CI) 0.80 to 4.41 with a random‐effects model, RR was 1.47, 95% CI [1.10 to 1.95] with a fixed‐effect model, and RR was 1.41 95% CI [1.06 to 1.88] after removing the high risk of bias study <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> (for high risk of bias for randomisation and allocation). </p> <p>Second, for CDAI &lt;1 50, we found that there was no difference between the intervention and control groups after conducting sensitivity analysis, RR was 1.02, 95% CI [0.67 to 1.56] with random‐effects model, RR was 1.08, 95% CI [0.94, 1 to 24] with fixed‐effect model, and RR was 1.02, 95% CI [0.67 to 1.56] after removing the high risk of bias study <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> (for unclear allocation and high risk of bias performance and detection blinding). </p> <p>Third, for the outcome fistula closure, short term we found a positive effect of the intervention than the control after conducting sensitivity analysis, RR was 1.48, 95% CI [1.12 to 1.96] random‐effects model, RR was 1.53, 95% CI [1.15 to 2.03] fixed‐effect model, and RR was 1.47, 95% CI [1.07 to 2.01] after removal of high‐risk studies <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> (for unclear allocation and high risk of bias for blinding and detection). </p> <p>Fourth, for the outcome fistula closure, long term we found a positive effect of the intervention after conducting sensitivity analysis RR was 1.42, 95% CI [1.09 to 1.87] for random‐effects model, RR was 1.47, 95% CI [1.12 to 1.94] for a fixed‐effect model, and RR was 1.48, 95% CI [1.10 to 1.99] after removal of high risk of bias studies <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> (for unclear allocation and high risk of bias for blinding and detection). </p> </section> </section> <section id="CD013070-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies due to the absence of a placebo or control group (<a href="./references#CD013070-bbs2-0010" title="ChoYB , LeeWY , ParkKJ , KimM , YooHW , YuCS .Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell transplantation2013;22(2):279-85. [PMID: 23006344]">Cho 2013</a>; <a href="./references#CD013070-bbs2-0024" title="ParkKJ , KimJS , KimW , KimHJ , LeeKY , Baik SH , et al.507 Allogeneic adipose-derived stem cells for the treatment of Crohn's perianal fistula: a Phase I/IIa clinical study. Gastroenterology2014;146(5):S-1016. ">Park 2014</a>; <a href="./references#CD013070-bbs2-0023" title="OnkenJ , JaffeT , CusterL .W1237 Long-term safety of prochymal adult mesenchymal stem cells in Crohn's disease. Gastroenterology2008;134(4):A-661. ">Onken 2008</a>; <a href="./references#CD013070-bbs2-0011" title="DigeA , HougaardHT , AgnholtJ , PedersenBG , TencerovaM , KassemM ,  et al.Efficacy of injection of freshly collected autologous adipose tissue Into perianal fistulas in patients with Crohn's disease. Gastroenterology2019;156(8):2208-2216.e1. ">Dige 2019</a>; <a href="./references#CD013070-bbs2-0025" title="SerreroM , GrimaudF , PhilandrianosC , ViséeC , SabatierF , GrimaudJC .Long-term safety and efficacy of local microinjection combining autologous microfat and adipose-derived stromal vascular fraction for the treatment of refractory perianal fistula in Crohn's disease. Gastroenterology2019;156(8):2335-2337.e2. ">Serrero 2019</a>). In addition, three non‐randomised studies (<a href="./references#CD013070-bbs2-0021" title="LazebnikL , KnyazevO , KonoplyannikovA , ParfenovA , RuchkinaI , RogozinaV , et al.T1751 Transplantation of allogenic mesenchimal stem cells is a new method of biological therapy of Crohn's disease. Gastroenterology2010;138(5):S-571. ">Lazebnik 2010</a>; <a href="./references#CD013070-bbs2-0017" title="KagramanovaA , Knyazev, O, KonoplyannikovA .P-068 The combined of mesenchymal stem cells and anticytokine therapy reduces the recurrence rate of Crohn's disease. Inflammatory Bowel Diseases2016;22(suppl-1):S31-S31. ">Kagramanova 2016</a>; <a href="./references#CD013070-bbs2-0018" title="KnyazevOV , IvanovichPA , GeorgievichKA , KagramanovaKA .Safety of mesenchymal stem cells therapy in patients with inflammatorybowel diseases a 5 year follow-up. Journal of Biotechnology &amp; Biomaterials2015;5(3):1-5. ">Knyazev 2015</a>) were excluded. Other reports of the same included studies were excluded as a primary study, but data were included in their primary studies as follow‐up data. One trial was withdrawn as the authors found that the protocol was not reflective of the clinical situation in question (<a href="./references#CD013070-bbs2-0013" title="WHO trial.Randomized, single-blind, placebo controlled multicenter phase III study to assess the efficacy and safety of expanded autologous adipose-derived stem cells (eASCs) (CX-401), for treatment of complex perianal fistulas in perianal Crohn's disease. FATT II: fistula Advanced Therapy Trial (II) - FATT II. EUCTR2008-004286-25-NL2008. ">FATT‐2 trial</a>), thus was added to the excluded studies. For reasons of exclusion see (<a href="#CD013070-fig-0001">Figure 1</a>). </p> <section id="CD013070-sec-0063"> <h5 class="title">Ongoing studies</h5> <p>We found nine ongoing studies (<a href="./references#CD013070-bbs2-0029" title="A clinical research study of an investigational new drug to treat perianal fistulas in patients with Crohn’s disease (CD). EU Clinical Trials Register. WexnerS , SandbornW , PanesJ , GilaberteI , GulatiP , ZhangB , et al.Design of a phase III, double-blind, randomized trial to evaluate the safety and efficacy of allogeneic stem cells (Darvadstrocel) for the treatment of complex perianal fistula(S) in patients with Crohn's disease (ADMIRE-CD II trial).. Diseases of the Colon and Rectum2020;63(6):e300. ">EUCTR2017‐000725‐12‐CZ</a>; <a href="./references#CD013070-bbs2-0030" title="A randomised controlled trial to assess the safety and effectiveness of stem cell transplantation using a reduced intensity regimen in patients with treatment resistant Crohn’s disease. ISRCTN registry. SnowdenJA , HawkeyC , HindD , SwabyL , MellorK , Emsley R et al,  Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators, European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology2019;19(1):82. ">ISRCTN17160440</a>; <a href="./references#CD013070-bbs2-0031" title="Evaluation of PROCHYMAL® adult human stem cells for treatment-resistant moderate-to-severe Crohn's disease. ClinicalTrials.gov. ">NCT00482092</a>; <a href="./references#CD013070-bbs2-0032" title="Evaluation of local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN's fistulas (ADICROHN2). NCT040105262019. ">NCT04010526</a>; <a href="./references#CD013070-bbs2-0033" title="Mesenchymal stem cells for the treatment of Perianal Fistulizing Crohn's Disease (PFCD). NCT045196712020. ">NCT04519671</a>; <a href="./references#CD013070-bbs2-0034" title="Study of mesenchymal Stem cells for the treatment of Ileal Pouch Fistula's in participants with Crohn's disease (IPAAF). NCT045196842020. ">NCT04519684</a>; <a href="./references#CD013070-bbs2-0035" title="Mesenchymal stem cells for the treatment of Rectovaginal Fistulas in participants with Crohn's disease (RVF). NCT045196972020. ">NCT04519697</a>; <a href="./references#CD013070-bbs2-0036" title="Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's ColitisOfficial title: A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis. Ongoing study. November 4, 2020. Contact author for more information.">NCT04548583</a>; <a href="./references#CD013070-bbs2-0037" title="Clinical study to evaluate efficacy and safety of ASC and fibringlue or fibringlue in patients with Crohn's fistula. NCT046124652020. ">NCT04612465</a>). For full characteristics of ongoing trials kindly see <a href="./references#CD013070-sec-0124" title="">Characteristics of ongoing studies</a> </p> </section> </section> </section> <section id="CD013070-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>The graphical presentation of the risk of bias is presented in <a href="#CD013070-fig-0002">Figure 2</a> and <a href="#CD013070-fig-0003">Figure 3</a>. Further details are presented in the <a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD013070-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013070-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013070-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013070-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013070-sec-0065"> <h4 class="title">Allocation</h4> <p>The random sequence generation method was clearly reported in five studies (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>) and was unclear in two (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> <p>It was mentioned that centralised randomisation was carried out in (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, and <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), but the method of allocation was not mentioned in ( <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>) so it was judged as unclear. It was computer‐generated in <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>, while in <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> randomisation was done in the immunology department with the researcher having no contact or knowledge of the patients entering the study. </p> <p>Three trials clearly reported the allocation concealment method through having centralised randomisation  <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> and <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), and one study (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) mentioned that the researcher responsible for randomisation is not in contact with, or has knowledge of, the patients. Four studies had an unclear method of allocation concealment (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> </section> <section id="CD013070-sec-0066"> <h4 class="title">Blinding</h4> <p>Four of the studies had a high risk of performance bias as they were open trials with un‐blinding of the participants (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). Three trials using placebo as a method of blinding but only two trials had a low risk of performance blinding (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>), while in the third trial (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) the risk was high as the authors stated that the saline used was apparent to contain no cells which caused the unblinding of the participants and personnel. </p> <p>On the other hand, five trials (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) stated clearly that they had a low risk of detection bias, while in two trials (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) the risk of detection bias was high, as the trials were open‐label, and no specific measure for blinding of the assessors was mentioned. </p> </section> <section id="CD013070-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>All the seven trials had a low risk of attrition bias (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> <p>All the seven studies mentioned that they performed an ITT analysis (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> <p>In (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>); eight patients withdrew from the placebo group before completing the one‐year follow‐up period due to the flare‐up of their disease and the need for either surgical intervention or early transplantation, and one patient withdrew after the randomisation. In the intervention group; one patient withdrew, and one patient died 20 days after the intervention. Although this created unbalance in the two groups, our primary outcomes measured (CDAI at 24 weeks and clinical remission) were not affected as the data on both were present in the primary study. The withdrawal of patients affected the outcome CDAI after one year and the authors had undergone implementation assuming the worst‐case scenario. </p> <p>In the case of long‐term fistula follow‐up &gt;1 year, we considered the attrition as high when assessing the certainty of evidence in the <a href="./full#CD013070-tbl-0001">summary of findings Table 1</a>. This is because all four studies have a high percentage of patients lost in the long‐term follow‐up (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). </p> </section> <section id="CD013070-sec-0068"> <h4 class="title">Selective reporting</h4> <p>We examined the trial registries against the published manuscript of the included studies to observe any differences in the following; the type of study, the collection sample, and the assigned primary outcomes. The trial registry of each of the included studies is presented in the <a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>. </p> <p>Five studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>) had a low risk of selective reporting. <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>h had an unclear risk of selective reporting. <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> had a high risk of selective reporting as the protocol of the study stated that the study is a case‐control trial with 22 participants in each arm. The published study included only 11 participants in each arm without mentioning the cause of the decline in the sample size. Also, the published paper stated that it was a randomised controlled open‐label trial. </p> </section> <section id="CD013070-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>The overall judgment was a high risk of bias in(<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>). The randomization included 50 participants with a range of diseases and this review relied on data from a subgroup of the 14 participants with Crohn's disease, this caused a judgment of unclear risk of bias. Also, there is a high risk of funding bias in this study due to sponsoring by (Cellerix) company where the Primary investigator holds a chair in the company and on the advisory board, he also holds two patents of the Cx401 cellular composition. </p> <p>In (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) there was a high risk of bias attributed to the suspension of the study before reaching the statistical power due to safety events, with the trial sponsored by a pharmaceutical company (Celularity Incorporated)<b>.</b> In <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>)there was a high risk of bias due to funding conflict, where the funder (TiGenix) had a role in the study design, data collection, analysis, interpretation, and writing of the final report of the study. </p> <p>In addition, in <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> there was a low risk of bias as the stem cells were obtained from a single donor, so the variation of results due to variation of donors was expectedly low. In other included RCTs using allogeneic stem cells; this risk of bias was unclear as in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) it was placental tissue, and in (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) it was commercially available mesenchymal cells, so we do not know if the cells came from single or multiple donors. In <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> there is a high risk of bias as the mesenchymal stem cells were prepared from five separate donors. </p> <p>However, in the other three studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) no risk of other forms of bias was detected. (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) included mainly male participants (21 males versus 1 female). </p> </section> </section> <section id="CD013070-sec-0070"> <h3 class="title" id="CD013070-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD013070-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn?s Disease</a> </p> <p>The main comparisons of stem cells versus placebo for medically refractory Crohn's disease‐Primary outcomes, Summary, and long‐term effects of the intervention are shown in <a href="./full#CD013070-tbl-0001">summary of findings Table 1</a>and additional <a href="#CD013070-tbl-0002">Table 1</a>. </p> <section id="CD013070-sec-0071"> <h4 class="title">1‐Primary Outcomes</h4> <section id="CD013070-sec-0072"> <h5 class="title">1.1 Clinical remission as defined by the primary studies</h5> <p>Clinical remission as defined by the primary studies is presented in <a href="#CD013070-fig-0004">Figure 4</a>; <a href="./references#CD013070-fig-0007" title="">Analysis 1.1</a>. More people achieved clinical remission with stem cell therapy (SCT) than with placebo/no SCT, (risk ratio (RR) 1.88, 95% confidence interval (CI) 0.80 to 4.41), studies = 3; participants = 301; low certainty of evidence; <a href="./references#CD013070-fig-0007" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD013070-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD013070-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The definition was variable; in <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a> it was defined as “free of active disease", the number of patients in each group was identical to Crohn’s Disease Activity Index (CDAI) &lt; 150. In (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) it was defined as clinical remission at 24 weeks with “closure of all treated external openings that were draining at baseline despite gentle finger compression”. In <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>, clinical remission induction was considered when CDAI ≤150 at four and six weeks. </p> </section> <section id="CD013070-sec-0073"> <h5 class="title">1.2 Clinical improvement by CDAI &lt; 150</h5> <p>The time frame assessment was different including 12 and 24 weeks. CDAI &lt;150 at 24 weeks was presented <a href="./references#CD013070-fig-0008" title="">Analysis 1.2</a> in four studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>) with (RR‐1.02 95% CI [0.67 to 1.56]; studies = 4; participants = 352; very‐low certainty of evidence; <a href="./references#CD013070-fig-0008" title="">Analysis 1.2</a>), and I<sup>2</sup> 68%; the impact of SCT is uncertain as the CIs are wide and cross the line of no effect.  </p> <p>Only two studies had patients with intestinal Crohn’s disease (CD) (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>). (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) showed improved CDAI after stem cells as compared to the control with (RR‐3.83 95% CI [0.91 to 16.07]; participants = 45), but the size of the study population was small with only 7.5% weight.  While the RR could not be calculated in <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> as none of the patients reached CDAI &lt; 150 in the two groups (intervention and control). <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> and <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> both aimed at the treatment of CD fistula, not the intestinal CD, thus, the baseline CDAI in both studies was low, with no significant change after the intervention. </p> </section> <section id="CD013070-sec-0074"> <h5 class="title">1.3 Fistula closure</h5> <p>Fistula closure was assessed in the studies dealing with perianal CD (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) with long‐term data available for all four studies. </p> <p>The short‐term outcome presented in [<a href="./references#CD013070-fig-0009" title="">Analysis 1.3</a>, <a href="#CD013070-fig-0005">Figure 5</a>] was assessed at eight weeks in (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>)and 24 weeks in (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). More people had fistula closure with SCT than with placebo/no SCT, (RR 1.48, 95% CI [1.12 to 1.96], studies = 4; participants = 269; low certainty of evidence; <a href="./references#CD013070-fig-0009" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD013070-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD013070-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The result for longer‐term fistula closure (one to four years) presented in the primary study in <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> or on follow‐up reports of the primary studies by the same authors in (<a href="./references#CD013070-bbs2-0071" title="GuadalajaraH , HerrerosD , De-La-QuintanaP , TrebolJ , Garcia-ArranzM , Garcia-OlmoD .Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. International Journal of Colorectal Disease2012;27(5):595-600.">Guadalajara 2012</a>; <a href="./references#CD013070-bbs2-0099" title="PanésJ , García-OlmoD , VanAG , ColombelJF , ReinischW , BaumgartDC , et al.Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology2018;154(5):1334-1342.e4.">Panés 2018</a>; <a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>) is presented in[<a href="./references#CD013070-fig-0010" title="">Analysis 1.4</a>,  <a href="#CD013070-fig-0006">Figure 6</a>]. More people had fistula closure in the longer term with SCT than with placebo/no SCT, (RR 1.42, 95% CI [1.09 to 1.87], studies = 4; participants = 250; low certainty of evidence; <a href="./references#CD013070-fig-0010" title="">Analysis 1.4</a>). </p> <div class="figure" id="CD013070-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD013070-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> </section> <section id="CD013070-sec-0075"> <h4 class="title">2‐Secondary Outcomes</h4> <section id="CD013070-sec-0076"> <h5 class="title">2.1 Clinical improvement</h5> <p> <ul id="CD013070-list-0015"> <li> <p><b><i>Regarding the Perianal Disease Activity Index (PDAI) score;</i> </b> there was a change in the score from the baseline presented at 12 and 24 weeks in three studies (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), where PDAI at 12 weeks I<sup>2</sup> = 82%. Therefore, a forest plot was done for PDAI after 12 weeks with no pooling of the results as stated in the protocol for any I<sup>2</sup> more than 75%, for more detail on sensitivity analysis (please see <a href="./references#CD013070-fig-0011" title="">Analysis 1.5</a>). PDAI at 24 weeks was associated with a mild decrease of (RR ‐0.35, 95% CI ‐1.57 to 0.86), studies = 3; participants = 247; <a href="./references#CD013070-fig-0012" title="">Analysis 1.6</a>). I<sup>2</sup> = 39% at 24 weeks. </p> </li> <li> <p><b><i>Regarding the Crohn’s Disease Activity Index (CDAI) score</i> </b> ; we found data on the change in the score from baseline at 24 weeks of CDAI presented in the studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>. There was a decrease in the score after 24 weeks. I<sup>2</sup> = 96% was high due to heterogeneity among studies, so a forest plot was done without pooling of the results as stated in the protocol for any I<sup>2</sup> more than 75% [<a href="./references#CD013070-fig-0013" title="">Analysis 1.7</a>]. In (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>) the outcome was not analysed quantitatively, the clinical response was defined as a decline &gt; 100 points in the CDAI score and was achieved in 10 patients out of 28 in the intervention group versus none in the placebo group. </p> </li> <li> <p><b><i>Data on change of Harvey‐Bradshaw Index (HBI) after 12 months</i> </b> was extracted from two studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>). There was a decline with intervention by (RR‐2.59, 95% CI ‐4.04, to1.14, studies = 2; participants = 124; <a href="./references#CD013070-fig-0014" title="">Analysis 1.8</a>), and I<sup>2</sup> of 40%. The total number of participants was 62 in the stem cell group and 62 in the placebo group. </p> </li> </ul> </p> </section> <section id="CD013070-sec-0077"> <h5 class="title">2.2 Endoscopic scores</h5> <p>We found data for different scores used in different studies. Only three studies used endoscopic scores for patients' assessment. In <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; the Simple endoscopic score for Crohn's disease (SES‐CD) was used while in <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>, and <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> the Crohn's Disease Endoscopic Index of Severity (CDEIS) score was used. The change in the score was measured after 12 weeks. There was no change in the score after treatment. Data were presented with forest‐plot only and no pooling was done as the I<sup>2</sup> was 92% (I<sup>2</sup> &gt; 75%was not conducted according to the protocol methodology) as shown in [<a href="./references#CD013070-fig-0015" title="">Analysis 1.9</a>]. </p> </section> <section id="CD013070-sec-0078"> <h5 class="title">2.3 Adverse events</h5> <p>We assessed total and serious adverse events as defined by the original studies.</p> <section id="CD013070-sec-0079"> <h6 class="title">2.3.1 Data on total adverse events</h6> <p>This was mentioned in four studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) with (RR 0.99, 95% CI [0.88 to 1.13], studies = 4; participants = 293; very low certainty of evidence; <a href="./references#CD013070-fig-0016" title="">Analysis 1.10</a>).  </p> <p>We presented adverse events as the number of patients suffering from one or more adverse events as dichotomous outcomes only.  In (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) "the count data" of the total number of events per patient (events/patients) was presented in the study, so we converted it to a dichotomous outcome (number of patients suffering from adverse events versus the number of patients not suffering from adverse events). In (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) the data were originally presented as the number of patients suffering from adverse events, thus no conversion was performed. </p> <p>The reported adverse events varied across studies; they included; headache, pyrexia, local reactions at the site of injection, non‐cardiac chest pain, upper respiratory tract infection, anaemia, leukopenia, thrombocytopenia, phlebitis, infections (viral, bacterial), nausea, and vomiting, abdominal pain, diarrhoea, and fistula. </p> <p>In <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), the adverse events were more frequent (76 in 19 patients) in the intervention group as compared to the placebo group (38 in 15 patients). </p> <p>In <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>, it was reported that 53 patients in the intervention group developed antibodies to human leukocyte antigen (HLA) class‐I while none in the placebo group developed those donor‐specific antibodies, but no immune reaction occurred and also there was no relation between the treatment response and the antibody response. </p> <p>In (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) total adverse events were found in 7/11 patients in the intervention group versus 11/11 patients in the control group. </p> </section> <section id="CD013070-sec-0080"> <h6 class="title">2.3.2 Data on serious adverse events</h6> <p>This was found in all the seven studies with (RR 1.22,  95% CI 0.88 to 1.67, studies = 7; participants = 433; low certainty of evidence; <a href="./references#CD013070-fig-0017" title="">Analysis 1.11</a>). </p> <p>Serious adverse events reported included; systemic hypersensitivity to the intervention, gastric ulcer perforation, Crohn’s disease flare, pneumonia, anal or perianal abscess, proctalgia, liver abscess. </p> <p>Only (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) reported the absence of serious adverse events in both the intervention and the control groups (zero events). </p> <p>It has to be noted that the trial of <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> stopped before enrolling the last two participants due to safety issues. As explained by the authors of <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>, the safety issues were reported in another study on rheumatoid arthritis (RA) patients, and those who received the intervention suffered from the following: (one patient had retinal artery spasm and one patient had an attack of acute myocardial infection), which led to the suspension of the RA trial. Other serious adverse events reported in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>); included anal (after 8.5 months) and colon cancer (after 74 days) on the long‐term follow‐up. The authors suspected that the cancers were related to the original disease, not the intervention, and argued that the duration of CD in those two patients was 46.8 years and 33.4 years, respectively. </p> <p>In <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>, one patient developed adenocarcinoma of the cecum with peritoneal carcinomatosis after 15 months from intervention and with a family history of colon cancer. </p> <p>In <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>, one patient in the placebo (fibrin glue injection) group reported a flare of Crohn’s disease with intra‐abdominal abscess and recovered on medical treatment. </p> </section> </section> <section id="CD013070-sec-0081"> <h5 class="title">2.4 Withdrawal due to adverse events</h5> <p>Withdrawal due to adverse events was only reported in three studies with a total number of participants of 250; 124 in the placebo group and 126 in the intervention group. In the first study <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, one patient in the active and one patient in the placebo group. The second study was (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), there were five patients from the active group and six patients in the placebo group who withdrew due to adverse events. In <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>, two patients in the intervention group and three patients in the control group withdrew due to adverse events and went on to receive a re‐operation, (RR0.78, 95% CI 0.32 to 1.89, studies = 3; participants = 272; very low certainty of evidence; <a href="./references#CD013070-fig-0018" title="">Analysis 1.12</a>). </p> <p>In <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, the authors stated that in the control group eight patients withdrew due to treatment failure, and underwent subsequent surgery or early transplantation, one patient died after 20 days from administration of the intervention. </p> </section> <section id="CD013070-sec-0082"> <h5 class="title">2.5 All‐Cause mortality</h5> <p>We found data for all‐cause mortality in all seven studies with a total number of participants of 440 patients; 234 in the intervention group and 206 in the control/placebo group. No patients died in the control/placebo group, while two patients died in the intervention group. One died in <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, while the other case was in <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> where one patient died from a cancer rectum in the long follow‐up study (<a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>). </p> <p>In <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), one patient died after 20 days from the intervention by sinusoidal obstructive syndrome diagnosed post‐mortem. He was suspected to have intraperitoneal sepsis and laparotomy was done but was negative, then he developed acute liver failure with no apparent history or previous biochemical data to support a definitive diagnosis. </p> <p>The effect estimate as calculated by (Peto odds ratio (OR) 5.51, 95% CI 5.51 [0.30, 101.02], studies = 7; participants = 440; <a href="./references#CD013070-fig-0019" title="">Analysis 1.13</a>). </p> </section> <section id="CD013070-sec-0083"> <h5 class="title">2.6 Quality of life scores‐ change after 12 weeks in inflammatory bowel disease Questionnaire (IBDQ) score </h5> <p>Quality of life was reported in four studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) with a total number of participants of 292; 152 in the intervention group and 140 in the placebo/control group. Different scores were used, but we found enough data for meta‐analysis of the IBDQ score, it was assessed both at baseline and at 12 weeks in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) and at 24 weeks in (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). The change in the score was calculated using the standardised mean difference (SMD); with (SMD 0.25, 95% CI 0.25 [‐0.18, 0.68], studies = 4; participants = 292; <a href="./references#CD013070-fig-0020" title="">Analysis 1.14</a>). The heterogeneity was I<sup>2</sup> = 50%. </p> </section> <section id="CD013070-sec-0084"> <h5 class="title">2.7 Additional outcomes found but not mentioned in the protocol methodology (C‐reactive protein (CRP), cytokines, and fecal calprotectin) </h5> <p>In <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>, the mean levels of cytokines did not differ from baseline to after intervention event with clinical response. </p> <p>In <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>, it was noted that only fecal calprotectin was decreased with the clinical response but CRP and cytokines showed no change. </p> <p>This laboratory outcome is important in the daily clinical practice for patients' assessment at baseline and follow‐up. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013070-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013070-sec-0085"></div> <p>All of the randomised controlled trials (RCTs) included patients with Crohn's disease (CD) refractory to one or more standard medical treatment, with variability from moderate to severe activity, either colitis or fistulising disease. As the main concept is not to expose treatment‐naive and responding‐patients to unknown risks. So in naive patients to treatment data are lacking. This is in accordance with the latest European Union guidelines in which Darvadstrocel (a suspension drug of expanded allogeneic adipose‐derived stem cells (eASCs)) was approved after the results of the Adipose‐Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE‐CD) trial (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), with subsequent approval in the UK, Switzerland, and Israel. The mesenchymal stem cells (MSCs) are indicated for treatment in case of the refractory disease to at least one standard or biological therapy for CD with mild or non‐active disease status, and prior conditioning of the fistula has been performed (<a href="./references#CD013070-bbs2-0115" title="Takeda Pharmaceutical Company Limited.Takeda submits new drug application to manufacture and market Darvadstrocel in Japan for treatment of complex perianal fistulas in adult patients with Crohn’s disease. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) news release2021;Online:Online. [NEWS RELEASE: https://www.takeda.com/newsroom/newsreleases/2021/takeda-submits-new-drug-application-to-manufacture-and-market-darvadstrocel--in-japan-for-treatment-of-complex-perianal-fistulas-in-adult-patients-with-crohns-disease/]">Takeda 2021</a>, <a href="./references#CD013070-bbs2-0114" title="Scott LesleyJ .Darvadstrocel: a  review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs2018;32(6):627-34.">Scott 2018</a>). A step‐wise algorithm was proposed in (<a href="./references#CD013070-bbs2-0072" title="GuadalajaraH , García-ArranzM , HerrerosMD , Borycka-KiciakK , LightnerAL , García-OlmoD .Mesenchymal stem cells in perianal Crohn’s disease. Techniques in Coloproctology2020;24(8):883-9.">Guadalajara 2020</a>) for using the approved Darvastrocel. Also, a protocol was outlined for standardisation of MSC dosing in perianal disease associated with CD (<a href="./references#CD013070-bbs2-0093" title="MolendijkI , van derMeulen-de JongAE , VerspagetHW , VeenendaalRA , HommesDW , BonsingBA , et al.Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn’s disease. European Journal of Gastroenterology &amp; Hepatology2018;30(10):1148-54.">Molendijk 2018</a>). </p> <section id="CD013070-sec-0086"> <h3 class="title" id="CD013070-sec-0086">Summary of main results</h3> <p>We included for the final qualitative and quantitative analysis seven RCTs; the total number of participants was 442, with 234 in the stem cell group and 208 in the placebo or control groups. It has to be noted that about 50% of the participants were from one RCT (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). </p> <p>Three RCTs assessed the main outcome of clinical remission (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>, <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). Clinical remission was achieved in the intervention group more than the control group with low certainty of evidence. But the definition of clinical remission was variable across studies, where two of the included studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>) were open‐labelled with most of the studied population in (<a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). Clinical remission and response are followed for a variable duration among studies (4, 6,12, 24 etc. weeks). Our results show that clinical remission may be achieved with the stem cell therapy (SCT) more than placebo or control, and there was no difference after conducting the sensitivity analysis for random‐effects versus fixed‐effect models or omitting high‐risk studies.  </p> <p>Four RCTs assessed the achievement ofCrohn’s Disease Activity Index ( CDAI) &lt;150 at 24 weeks (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>), although the CDAI decrease was not the primary outcome in most of the studies. There was no apparent CDAI change after 24 weeks of the intervention. (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) was the only study showing improved CDAI to &lt; 150 after the 24 weeks from the administration of the SCT as compared to the control, however, the study weight was only 7.5% due to the small size of the studied population. While (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>) stated that none of the patients reached the target CDAI at 24 weeks, so no risk ratio (RR) could be calculated for this study. In addition, two of the four included studies presented with normal baseline CDAI as they were examining the fistulising, not the inflammatory intestinal, a subcategory of CD fixed‐effect( <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> and <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). The level of certainty of the evidence was very low. Our results show that CDAI &lt; 150 at 24 weeks may show no difference with the SCT as compared to the placebo or control, and there was no difference after conducting the sensitivity analysis for random‐effects versus fixed‐effect models or omitting high‐risk studies.  </p> <p>Four RCTs assessed the early fistula closure (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), although the time of determining the outcome was different, where (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>) was at eight weeks, while (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>)were at 24 weeks. It was assessed both clinically and with magnetic resonance imaging (MRI) with low certainty of evidence. Our results show that fistula closure in the short term may be achieved with the stem cell therapy more than placebo or control, and there was no difference after conducting the sensitivity analysis for random versus fixed‐effect models or omitting high‐risk studies.  </p> <p>Four RCTs assessed the long‐term follow‐up of fistula closure after one to several years (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>; <a href="./references#CD013070-bbs2-0099" title="PanésJ , García-OlmoD , VanAG , ColombelJF , ReinischW , BaumgartDC , et al.Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology2018;154(5):1334-1342.e4.">Panés 2018</a>; <a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>; <a href="./references#CD013070-bbs2-0071" title="GuadalajaraH , HerrerosD , De-La-QuintanaP , TrebolJ , Garcia-ArranzM , Garcia-OlmoD .Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. International Journal of Colorectal Disease2012;27(5):595-600.">Guadalajara 2012</a>) are presented. The number of patients was 250 with low certainty of evidence. The data were collected from published papers with long‐term follow‐up of the original studies (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>), respectively. In <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>, long‐term follow‐up study (after four years) (<a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>), three of the placebo group received SCT after two years from the original study. One study (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>) stated both the short‐ and long‐term follow‐up after one year results of fistula healing. It was noticed that attrition was high in all studies in long‐term follow‐up of fistula healing, which resulted in a downgrading of the certainty of evidence to low. Our results show that fistula closure long term may be achieved with the SCT more than placebo or control, and there was no difference after conducting the sensitivity analysis for random‐effects versus fixed‐effect models or omitting high‐risk studies.  </p> <p>There were only two dose‐escalation studies (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) where the effect on fistula closure was decreased by increasing the dose of stem cells in (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>), or no effect to increasing the dose in (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>). Further analysis is needed to determine the exact effect of increasing the dose of stem cells on fistula healing. </p> <p>The total number of adverse events was assessed in four studies (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). There was no difference between the intervention and the control groups regarding the number of adverse events, with very low certainty of evidence. </p> <p>All seven RCTs assessed the number of patients with serious adverse events (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), although the definition was different across studies. This was expected as most of the studies are phase II dealing mainly with safety issues as the primary outcome. The outcome had a low certainty of evidence. There were different definitions of what constitutes a serious adverse effect.  Autologous stem‐cell transplantation in treatment‐refractory Crohn's disease (ASCTIC) trial authors (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) concluded that haematopoietic stem cells (HSCs) did not achieve clinical remission and were associated with increased harm due to adverse events, thus there are no data to support the continuation of the trial on a large scale. In haematopoietic stem cell transplantation (HSCT), infection was the most dangerous and common adverse event. This is related to pancytopenia resulting from conditioning chemotherapeutic regimen, which as the authors of the original study (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) declared, could be the cause of death of the patient who died from sinusoidal obstruction syndrome. It is mentioned in <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> that the study was stopped due to safety issues in a concomitant study using PDA‐100 stem cells, but we did not find any publication on the topic stated by the authors "Two SAEs were seen in a study of rheumatoid arthritis and led to the suspension of enrollment in this study". Thus safety issues concerning PDA‐100 have to be addressed further. Only one patient died during the conduct of the study in all the six studies, the patient was in the intervention arm of (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>). While only in one of the included studies (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) one patient died from cancer cecum on long‐term follow‐up study by (<a href="./references#CD013070-bbs2-0041" title="BarnhoornMC , WasserMNJM , RoelofsH , MaljaarsWJ , MolendijkI , BonsingBA , et al.Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. Journal of Crohn's &amp; Colitis2020;14(1):64-70.">Barnhoorn 2020</a>). </p> <p>Only three studies reported on the patients' withdrawal caused by adverse events (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). We found that the withdrawal of patients due to adverse events was higher in the control group compared to the intervention group with very low certainty of evidence. </p> </section> <section id="CD013070-sec-0087"> <h3 class="title" id="CD013070-sec-0087">Overall completeness and applicability of evidence</h3> <p>There is an apparent heterogeneity among the studies regarding; the doses and types of stem cells (SCs) used, route of administration of the intervention, outcome measures, and follow‐up duration, adverse events reported, concomitant medications given to participants, and definition of refractory disease for study inclusion. </p> <p>There is an age restriction for children and also pregnant women due to safety and ethical issues related to SCs. In addition, the elderly were restricted in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>) (age &lt; 50 years) and in(<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> ) (&lt; 75 years). No gender restriction was observed among the trials, but there was inequality in the female/male ratio in (<a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> ) where only one female was included. </p> <p>The effect of using multiple donors versus a single donor as a source ofSCs, and autologous versus allogeneic stem cells on the immune system is still an unresolved issue. </p> <p>The local injection into the fistula could be more beneficial, and with fewer side effects when compared to systemic infusion, especially when using mesenchymal stem cells (MSCs). </p> <p>Crohn’s Disease Activity Index (CDAI) is a subjective outcome (symptom dependent) through questionnaires, and most of the studies lack performance blinding which makes the certainty of evidence very weak. A proposal of other objective outcomes is more proper to use in clinical trials using stem cells in refractory CD. On the other hand; fistula closure is assessed clinically or by MRI which is more objective. </p> <p>Laboratory cytokines and inflammatory markers are not changed in relation to the clinical response in early follow‐up, but it could more relevant if used in the long term. </p> </section> <section id="CD013070-sec-0088"> <h3 class="title" id="CD013070-sec-0088">Quality of the evidence</h3> <p>We used the GRADE approach (<a href="./references#CD013070-bbs2-0070" title="GRADEpro GDT.Version accessed 3 July 2018. Hamilton (ON): GRADE Working Group, McMaster University, 2015.">GRADEpro GDT</a>) to assess the certainty of the evidence for the comparison between stem cell therapy and placebo for the induction of remission of medically refractory CD. We used the GRADEPro integration in <a href="./references#CD013070-bbs2-0105" title="RevMan Manager Web (RevMan Web).Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>. </p> <p>There were significant problems with risk of bias lead to downgrading risk of bias; most of the studies had a high or unclear risk of bias of randomisation (two unclear <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> and <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), allocation concealment (four unclear <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a><a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>), and blinding (five high risk of bias <a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>; <a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). However, most of the unblinded studies had a low risk of detection bias except for two studies (<a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a>; <a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a>). This leads to downgrading the risk of bias by one point only. Blinding of the intervention was hard to accomplish due to the structural appearance of the stem cells solution which is different from saline, the studies which tried blinding used albumin (<a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>) or used opaque bags as (<a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a>), or the conditioning procedure used for the preparation of stem cells from the patient (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>). </p> <p>Moreover, concerns about the small number of the studied population lead to downgrading imprecision. No other issues regarding indirectness as all the outcomes in the summary of findings table were clinically relevant to the patients. Furthermore, publication bias was downgraded in one outcome (CDAI &lt; 150 at 24 weeks) as two studies were presented as abstract only (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a>; <a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>) and no published complete manuscript was found, also we contacted the authors for further data and are waiting for their reply. </p> </section> <section id="CD013070-sec-0089"> <h3 class="title" id="CD013070-sec-0089">Potential biases in the review process</h3> <p>We did a thorough screening of the meta‐analyses, systematic reviews, reviews, editorials, conference proceedings, and grey literature for the inclusion of possible studies related to our topic. We found four Russian studies published in English (<a href="./references#CD013070-bbs2-0017" title="KagramanovaA , Knyazev, O, KonoplyannikovA .P-068 The combined of mesenchymal stem cells and anticytokine therapy reduces the recurrence rate of Crohn's disease. Inflammatory Bowel Diseases2016;22(suppl-1):S31-S31. ">Kagramanova 2016</a>; <a href="./references#CD013070-bbs2-0018" title="KnyazevOV , IvanovichPA , GeorgievichKA , KagramanovaKA .Safety of mesenchymal stem cells therapy in patients with inflammatorybowel diseases a 5 year follow-up. Journal of Biotechnology &amp; Biomaterials2015;5(3):1-5. ">Knyazev 2015</a>; <a href="./references#CD013070-bbs2-0019" title="KnyazevOV , KagramanovaAV , FadeevaNA , LishchinskayaAA , BoldyrevaON , NoskovaKK , et, al.Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy. Terapevticheskii arkhiv2018;90(2):47-52. ">Knyazev 2018</a>; <a href="./references#CD013070-bbs2-0020" title="KnyazevO , KagramanovaA , LischinskayaA , KorneevaI , ZvyaglovaM , BabayanA , et al.Stem cell therapy for perianal Crohn’s disease. Proceedings of the Latvian Academy of Sciences (Section B)2020;74(2 (725)):68–74. ">Knyazev 2020</a>) that compared the standard medical intervention versus stem cells combined with medical intervention in CD, but all those studies were reported as case‐control with no mention of randomisation, allocation concealment, or blinding in their published data.  Also, no clinical trial registry was found in the published manuscripts. We tried contacting the authors for further information, but they did not respond, and through a consensus between the review authors we removed them as non‐RCT studies and presented them in the (<a href="./references#CD013070-sec-0122" title="">Characteristics of excluded studies</a>). </p> <p>The adverse effects varied immensely in their reporting across the studies, and we tried to find common ground for extraction and analysis through discussion with (AFN). We divided the adverse effects into (total adverse events) including all the adverse events that occur to the patients regardless of their severity, and (serious adverse events) that are life‐threatening or requiring hospitalisation or surgical intervention. Mortality was recorded as a separate outcome and discussed narratively. </p> <p>There was a limitation on the published data, where the authors of two conducted studies were published only as abstracts (<a href="./references#CD013070-bbs2-0027" title="ArturoJ , LucenaC , PerezC , EstebanC , Sandoval vivas AL, Bastidas Y et al.Efficacy of autologous expanded bone marrow derived mesenchymal stem cells (axBM-MSC) in the treatment of patients with chron's disease who have failed to standard therapy: an open-label, randomized controlled clinical trial phase II. Cytotherapy2017;19(5):e23. ">Arturo 2017</a> and <a href="./references#CD013070-bbs2-0028" title="Lichtiger, S.Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. American Journal of Gastroenterology2012;1:S689. ">Lichtiger 2012</a>) with foreseeable full manuscript publication. We tried to contact the authors, but we did not receive any response, so these studies were moved to (<a href="./references#CD013070-bbs1-0003" title="">Studies awaiting classification</a>). Both studies used the systematic injection of SCs. We re‐contacted the authors on October 2021 and are awaiting their response. </p> <p>We did not explore the Chinese and Korean databases with limitations to the English databases containing the abstracts of the studies, although we did not limit the search to the English‐written manuscripts; we found none in the English databases. </p> <p>There was an apparent issue regarding funding, as most of the included studies had either funding for the cellular component or support for the authors to publish as shown in (<a href="./references#CD013070-sec-0121" title="">Characteristics of included studies</a>). The cost of stem cell preparation or purchase is high, thus it is difficult for the researchers to obtain the stem cells without funding. This could be resolved by supplying this area of research through non‐profit clinical organisations as ECCO, which funded <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>, or through applying strict regulations prohibiting pharmaceutical companies from controlling the data collection and subsequent publication, where this right remains in the hands of an independent group of investigators. </p> </section> <section id="CD013070-sec-0090"> <h3 class="title" id="CD013070-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>We assessed the systematic reviews published in the same topic area that shed the light on some data, but we found some shortcomings. </p> <p>We noted multiple publications of different records for the same study in the following included studies (<a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a>; <a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>; <a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a>; <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>). This caused confusion in most of the published meta‐analyses and systematic reviews, where the authors included the population and the events twice, which caused a fault in the calculation of the results. Consequently, when a study (e.g. <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a>), which included over half of the studied population, this duplicate calculation will increase the weight of the study, the effect estimate of the intervention, and its confidence interval. This duplicate calculation was noticed in the following meta‐analyses (<a href="./references#CD013070-bbs2-0053" title="CiccocioppoR , KlersyC , LefflerDA , RogersR , BennettD , CorazzaGR .Systematic review with meta-analysis: Safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open2019;3(3):249-60.">Ciccocioppo 2019</a>; <a href="./references#CD013070-bbs2-0049" title="Castro-PoceiroJ , Fernández-ClotetA , PanésJ .Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. Immunotherapy2018;10(14):1203-17.">Castro‐Poceiro 2018</a>; <a href="./references#CD013070-bbs2-0046" title="CaoY , SuQ , ZhangB , ShenF , LiS .Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Research &amp; Therapy2021;12(1):32.">Cao 2021</a>; <a href="./references#CD013070-bbs2-0051" title="ChengF , HuangZ , LiZ .Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology2019;23(7):613-23.">Cheng 2019</a>). </p> <p>We noticed that some meta‐analyses did not include the <a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> study in their final results, which may have been caused by it not being apparent by the keywords used in their search, which also occurred in our study (we found the study through manual search of references in the review articles). This occurred in (<a href="./references#CD013070-bbs2-0102" title="QiuX , Feng J-R, Chen L-P, LiuS , ZhangM , ZhouZ , et al.Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: a systematic review and meta-analysis. Medicine2017;96(26):e7381.">Qiu 2017</a>; <a href="./references#CD013070-bbs2-0046" title="CaoY , SuQ , ZhangB , ShenF , LiS .Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Research &amp; Therapy2021;12(1):32.">Cao 2021</a>). </p> <p>Also, most of the meta‐analyses included one‐arm trials, dose‐escalation trials with no control group, case‐control, retrospective, and case series studies, which weakened the quality of evidence in their results and overestimated the effect of SCs. This happened in ; <a href="./references#CD013070-bbs2-0046" title="CaoY , SuQ , ZhangB , ShenF , LiS .Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Research &amp; Therapy2021;12(1):32.">Cao 2021</a>; <a href="./references#CD013070-bbs2-0053" title="CiccocioppoR , KlersyC , LefflerDA , RogersR , BennettD , CorazzaGR .Systematic review with meta-analysis: Safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open2019;3(3):249-60.">Ciccocioppo 2019</a>; <a href="./references#CD013070-bbs2-0049" title="Castro-PoceiroJ , Fernández-ClotetA , PanésJ .Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. Immunotherapy2018;10(14):1203-17.">Castro‐Poceiro 2018</a>; <a href="./references#CD013070-bbs2-0051" title="ChengF , HuangZ , LiZ .Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis. Techniques in Coloproctology2019;23(7):613-23.">Cheng 2019</a>; <a href="./references#CD013070-bbs2-0087" title="LightnerAL , FaubionWA .Mesenchymal stem cell injections for the treatment of perianal Crohn's disease: what we have accomplished and what we still need to do. Journal of Crohn's &amp; Colitis2017;11(10):1267-76.">Lightner 2017</a>; <a href="./references#CD013070-bbs2-0102" title="QiuX , Feng J-R, Chen L-P, LiuS , ZhangM , ZhouZ , et al.Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: a systematic review and meta-analysis. Medicine2017;96(26):e7381.">Qiu 2017</a>; <a href="./references#CD013070-bbs2-0117" title="TurseEP , DaileyFE , NaseerM , PartykaEK, BraggJD , TahanV .Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature. Stem Cells and Cloning : Advances And Applications2018;11:95-113.">Turse 2018</a>). </p> <p>Finally, some meta‐analyses used a non Crohn's disease population such as the <a href="./references#CD013070-bbs2-0075" title="HerrerosMD , Garcia-ArranzM , GuadalajaraH , De-La-QuintanaP , Garcia-OlmoD , FATT Collaborative Group.Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Diseases of the Colon and Rectum2012;55(7):762-72.">Herreros 2012</a> study in their final results. This happened in <a href="./references#CD013070-bbs2-0046" title="CaoY , SuQ , ZhangB , ShenF , LiS .Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Research &amp; Therapy2021;12(1):32.">Cao 2021</a>;  <a href="./references#CD013070-bbs2-0049" title="Castro-PoceiroJ , Fernández-ClotetA , PanésJ .Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. Immunotherapy2018;10(14):1203-17.">Castro‐Poceiro 2018</a>;  <a href="./references#CD013070-bbs2-0053" title="CiccocioppoR , KlersyC , LefflerDA , RogersR , BennettD , CorazzaGR .Systematic review with meta-analysis: Safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open2019;3(3):249-60.">Ciccocioppo 2019</a>. </p> <p>The British Society of Gastroenterology (<a href="./references#CD013070-bbs2-0083" title="LambCA , KennedyNA , RaineT , HendyPA , SmithPJ , LimdiJK , et al.British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut2019;68(Suppl 3):s1.">Lamb 2019</a>) commented on the use of autologous HSCs used in (<a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a>), as a hazardous intervention, and that the authors did not achieve their intended outcome but recommended further research in that refractory CD population. Moreover, they found <a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> results encouraging, regarding the effect of treatment by allogeneic MSCs, and noted that 34% of the control group achieved remission due to removal of affected tissue and fibrin glue interventions only. In addition, National Institute for Health and Care Excellence (NICE) guidelines mentioned the ADMIRE‐CD trial in their (Technology appraisal guidance) as a promising new intervention for refractory CD patients with perianal fistula (<a href="./references#CD013070-bbs2-0096" title="NICE.Darvadstrocel for treating complex perianal fistulas in Crohn’s disease. National Institute for Health and Care Excellence (NICE)Guidelines, Technology Appraisal Guidance 9 January 2019;[TA556]:1-24.">NICE 2019</a>). American College of Gastroenterology (ACG)(<a href="./references#CD013070-bbs2-0086" title="LichtensteinGR , Loftus EV , IsaacsKL , RegueiroMD , GersonLB , SandsBE .ACG Clinical Guideline: management of Crohn's disease in adults. Official journal of the American College of Gastroenterology (ACG)2018;113(4):481-517.">Lichtenstein 2018</a>) did not mention the SCT, but mentioned the seton placement alone as a plausible intervention with moderate quality of evidence. As for American Gastroenterological Association (AGA) they did not mention stem cell therapy (SCT) in their most updated guidelines. (<a href="./references#CD013070-bbs2-0064" title="FeuersteinJD , HoEY , ShmidtE , SinghH , Falck-YY, SultanS , et al.AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology2021;160(7):496-2508.">Feuerstein 2021</a>), however, the European Crohn’s and Colitis Organisation (ECCO) (<a href="./references#CD013070-bbs2-0039" title="AdaminaM , BonovasS , RaineT , SpinelliA , WarusavitarneJ , ArmuzziA , etal, and European Crohn’s and Colitis Organisation [ECCO].ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis2020;14(2):155-168.">Adamina 2020</a>) mentioned adipose tissue‐derived mesenchymal stem cells, either allogeneic or autologous, as a safe and effective treatment in patients with complex perianal fistula, in their most updated guidelines version. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013070-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-01" target="_blank"><b></b></a></p> </div><img alt="The flow diagram of the new search strategy (updated in 20 March 2021) Using COVIDENCE for screening (COVIDENCE Program)" data-id="CD013070-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>The flow diagram of the new search strategy (updated in 20 March 2021) Using COVIDENCE for screening (COVIDENCE Program) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013070-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013070-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013070-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013070-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013070-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 1: Stem cell therapy versus placebo or control, Outcome: Clinical remission" data-id="CD013070-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 1: Stem cell therapy versus placebo or control, Outcome: Clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 2: CDAI &lt;150 at 24 weeks" data-id="CD013070-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 2: CDAI &lt;150 at 24 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 3: Stem cell therapy versus placebo or control, Outcome: Fistula Closure short‐term" data-id="CD013070-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 3: Stem cell therapy versus placebo or control, Outcome: Fistula Closure short‐term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 4: Stem cell therapy versus placebo or control, Outcome: Fistula closure in long‐term Follow up of original studies" data-id="CD013070-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 4: Stem cell therapy versus placebo or control, Outcome: Fistula closure in long‐term Follow up of original studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 5: PDAI Change at week 12" data-id="CD013070-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 5: PDAI Change at week 12</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 6: PDAI change at week 24" data-id="CD013070-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 6: PDAI change at week 24</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 7: CDAI change at 24 weeks" data-id="CD013070-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 7: CDAI change at 24 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 8: Harvey Bradshow Index (HBI) change after 12 months" data-id="CD013070-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 8: Harvey Bradshow Index (HBI) change after 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 9: Endoscopic score change after 12 weeks" data-id="CD013070-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 9: Endoscopic score change after 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 10: Total Adverse Events" data-id="CD013070-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 10: Total Adverse Events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 11: Serious Adverse Events" data-id="CD013070-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 11: Serious Adverse Events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 12: Withdrawal due to adverse events" data-id="CD013070-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 12: Withdrawal due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 13: All cause mortality" data-id="CD013070-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 13: All cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013070-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/urn:x-wiley:14651858:media:CD013070:CD013070-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Stem cells versus Control, Outcome 14: Quality of life score (change from base line) IBDQ" data-id="CD013070-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_t/tCD013070-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Stem cells versus Control, Outcome 14: Quality of life score (change from base line) IBDQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/media/CDSR/CD013070/image_n/nCD013070-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013070-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn?s Disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn's Disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Induction of Remission in Medically Refractory Crohn's Disease<br/><b>Setting:</b> Specialised centres<br/><b>Intervention:</b> Stem Cell<br/><b>Comparison:</b> Placebo or Control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Placebo or Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Stem Cell</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(252 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/>(0.80 to 4.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The three studies that included data about clinical remission were Hawkey 2015, Melmet 2015, and Panes 2016. Each had a different definition of clinical remission. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &lt;150 at 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(339 to 789) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b><br/>(0.67 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data regarding the CDAI at 24 weeks was not the primary outcome of any of the included studies. They also used different cut‐offs and different ranges. Here we included local and systemic stem cell therapy. Zhang et al 2018 had zero weight, as the number of events was 0 in both intervention and control arms (the authors stated that no patients achieved CDAI &lt;150 at 24 weeks). The baseline CDAI was already low in the studies examining fistula management. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula Closure short‐term<br/>assessed with: Clinically or MRI </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>349 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(391 to 684) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.48</b><br/>(1.12 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula closure was assessed in four studies. Garcia‐Olmo et al 2009 assessed the outcome at 8 weeks, while Molendijk et al 2015, Panes et al 2016, and Zhou et al 2020 assessed the outcome at 24 weeks. It was assessed both clinically and with MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fistula closure in long‐term Follow up of original studies<br/>assessed with: Clinicaaly or MRI </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b><br/>(425 to 729) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b><br/>(1.09 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>h,</sup><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data on the long‐term effects were gathered from published papers after a long‐term follow‐up of the original studies. Except Zhou 2020, which reported their long‐term 1‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total Adverse Events<br/>assessed with: Clinically </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>730 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>723 per 1000</b><br/>(643 to 825) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.88 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,</sup><sup>k,</sup><sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The range of total adverse effects stated was very wide across studies, from minimal abdominal pain or low‐grade fever to sepsis and the need for surgical operation. We collected the data on total adverse events without stating the level, or severity of the adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious Adverse Events<br/>assessed with: Clinically </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b><br/>(99 to 187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b><br/>(0.88 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>m,</sup><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 7 studies stated the number of patients suffering from serious adverse effects, mostly because these trials are addressing the safety issues of stem cell administration. The different definitions of serious adverse events among the studies make the outcome assessment heterogeneous and inconsistent, some studies did not define clearly what a serious adverse event stands for. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b><br/>(24 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b><br/>(0.32 to 1.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>o,</sup><sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both Panes 2016 and Zhou 2020 stated clearly that the withdrawal was due to adverse events. But in Hawkey 2015, it was stated that one patient from the control group withdrew directly after randomization, and one patient in the active group withdrew after 26 weeks of mobilization for accelerated transplantation. In Zhou 2020, the patients withdrew due to adverse effects to receive a subsequent reoperation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423896885310176737" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423896885310176737</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The risk of bias is downgraded to serious, as two of the three studies are open‐label, thus the participants are not blinded including Panes 2016 which contains most of the studied population, and this outcome is a subjective outcome.<br/><sup>b</sup> The inconsistency was downgraded by one level as the heterogeneity in the included studies was high in the form of the variability of the results due to different definitions of the outcome.<br/><sup>c</sup> Inconsistency downgraded by one level to serious as the level of CDAI at the start of the studies varied according to the route of intervention, CDAI was low or normal at baseline in local intervention, while high at baseline in systemic intervention.<br/><sup>d</sup> The imprecision was downgraded by one level to serious as the RR is 1.08 with CI 0.94‐1.24, which makes the intervention equally capable of doing harm or benefit.<br/><sup>e</sup> Publication bias strongly suspected and downgraded by one level as there were two abstracts of unpublished complete data (Arturo 2017 and Lichtiger 2012).<br/><sup>f</sup> The outcome was downgraded by one point to serious as the risk of allocation concealment was unclear in three studies (Garcia‐Olmo 2009 and Zhou 2020), and randomization was unclear in (Zhou 2020). Although the risk of bias for blinding of participants is high in (Zou 2020, Panes 2016, Garcia‐Olmo 2009), and unclear in (Molendijk 2015); three of these studies had a low risk for detection bias, while only Zhou 2020 had high risk. Also, the outcome is an objective outcome that doesn't change by the participant or the personnel being unblinded.<br/><sup>g</sup> Imprecision was downgraded by one level to serious as the number of the studied population was small.<br/><sup>h</sup> The risk of bias is downgraded to serious: as there are a lot of patients lost to long‐term follow‐up (missing data), thus high attrition.<br/><sup>i</sup> The imprecision was downgraded by one level to serious as the number of patients and number of events were low. Also, the confidence interval was wide.<br/><sup>j</sup> The risk of Bias was downgraded by one level to serious as three of the four studies had a high risk of performance bias and one unclear risk. Considering that the outcome is reporting about the adverse events, which are mostly subjective in the case of mild and moderate adverse events, we downgraded by one level.<br/><sup>k</sup> Inconsistency is downgraded by one level to serious as the studies reported the category (All adverse events differently)<br/><sup>l</sup> Impression was downgraded by one level as the number of participants was low<br/><sup>m</sup> The risk of bias was downgraded by one level, as 5 trials had high‐performance bias (open‐label trials) but it is not an objective outcome, and allocation concealment is unclear in 4 trials and randomization is unclear in 2 trials.<br/><sup>n</sup> Imperceision is downgraded by one level to serious because the CI was very wide (0.89‐1.93), so we are not certain if the intervention causes benefit or harm. <br/><sup>o</sup> Indirectness was downgraded by one level to seriuos as the causes of withdrawal in (Hawkey 2015) were not stated as due to adverse events.<br/><sup>p</sup> Imprecision was downgraded by two levels to very serious due to the low number of participants and wide CI (0.33‐1.91), so we are not confident if the intervention causes benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Stem Cell compared to Placebo or Control for Induction of Remission in Medically Refractory Crohn?s Disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013070-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data Extracted from the included studies:</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0001" title="Garcia-OlmoD , HerrerosD , PascualI , PascualJA , Del-ValleE , ZorrillaJ , et al.Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Diseases of the Colon and Rectum2009;52(1):79-86. [PMID: 19273960]">Garcia‐Olmo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0004" title="MolendijkI , BonsingBA , RoelofsH , PeetersKC , WasserMN , DijkstraG , et al.Allogeneic bone marrow-derived mesenchymal stromalcCells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology2015;149(4):918-27.e6. [PMID: 26116801]">Molendijk 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0003" title="MelmedGY , PandakWM , CaseyK , AbrahamB , ValentineJ , SchwartzD , et al.Human placenta-derived Cells (PDA-001) for the treatment of moderate-to-severe Crohn's disease: a phase 1b/2a study. Inflammatory Bowel Diseases2015;21(8):1809-16. [PMID: 25985246]">Melmed 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0005" title="PanesJ , Garcia-OlmoD , Van AsscheG , ColombelJF , ReinischW , BaumgartDC , et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England)2016;388(10051):1281-90. [PMID: 27477896]">Panes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0006" title="ZhangJ , LvS , LiuX , SongB , ShiL .Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial. Gut and Liver2018;12(1):73-8. [PMID: 28873511]">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0002" title="HawkeyCJ , AllezM , ClarkMM , LabopinM , LindsayJO , RicartE , et al.Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA2015;314(23):2524-34. [PMID: 26670970]">Hawkey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013070-bbs2-0007" title="ZhouC , LiM , ZhangY , NiM , WangY , XuD , et al.Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial [Z]. Stem Cell Research &amp; Therapy2020;11(1):124. ">Zhou 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>CCC of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In ALL study</p> <p>43.33, SD 9.9</p> <p>I: mean 42.64, SD 10.93</p> <p>P: 43.99, SD 8.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age: 38<br/>Group 1:<br/>Mean: 40.4 (27‐54)<br/>Group 2:<br/>Mean: 40.8 (37‐47)<br/>Group 3:<br/>Mean: 33.4 (21‐48)<br/>Placebo:<br/>Mean: 37.3 (27‐49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unit: mean 35.3 SD 14</p> <p>4 units: mean 36.2 SD 11.6</p> <p>Placebo: mean 36.5 SD7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: mean 39.0 (13.1)</p> <p>P: mean 37.6 (13.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt;18y‐70 years</p> <p>I:34.3 (21‐44)</p> <p>P: 32.7(20‐41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:<br/>Median: 34.1<br/>IQR: (26.1‐41.2)<br/>P:<br/>Median: 30.6<br/>IQR:(24.0‐37.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range from; 12‐51</p> <p>28.86 ± 10.13</p> <p>I: 24.4 ± 5.0<br/>C: 24.9 ± 5.4 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all study 24/25</p> <p>M/F</p> <p>I: 10/14</p> <p>P: 14/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male in 4 groups:</p> <p>4/5</p> <p>4/5</p> <p>1/5</p> <p>3/6</p> <p>M/F: 12/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unit:53.3% M/F:8/7</p> <p>4 units:33.3 % 5/10</p> <p>placebo:43.8% 7/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 60/47</p> <p>P: 56/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:</p> <p>24/17</p> <p>P:</p> <p>26/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women:</p> <p>I: 13/23</p> <p>P: 11/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 female</p> <p>21 male</p> <p>(M/F)<br/>Intervention: 11/0<br/>Control: 10/1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease duration in years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In years in 4 groups</p> <p>I: 7.6 (5‐11)</p> <p>II: 16.8 (5‐28)</p> <p>III: 13.2 (2‐23)</p> <p>Placebo: 6.8 (1‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>I unit:18.5 yrs SD 13.8</p> <p>4 units:10.4 yrs SD 10.7</p> <p>placebo: 16.2 yrs SD9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 12.1 (10.0)</p> <p>P: 11.3 (8.9) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7 (2‐15)<br/>C: 8 (3‐14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 14.9 y</p> <p>P: 11.2 y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease location</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rectovaginal fistula = 8/49<br/>I= 4, P= 4<br/>Suprasphincteric fistulous tract= 30/49<br/>I= 14, P= 16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perianal</p> <p>Group 1:<br/>L1= 1, L2 =3, L3=1 </p> <p>Group 2:<br/>L1= 1, L2=2,L3= 2<br/>Group 3:<br/>L1=2,L2=1,L3=2<br/>Placebo:<br/>L1=1,L2=2,L3=2, L3+L4=1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perianal</p> <p>High inter‐sphincteric, trans‐sphincteric, extra‐sphincteric or supra‐sphincteric.</p> <p>(?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I/C</p> <p>Ileal: 14/17</p> <p>Colonic:18/14</p> <p>Ileocolonic:9/10</p> <p>Isolated upper:6/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention:<br/>Ileum (L1) 1 (9.1%) Colon (L2) 4 (36.4%) Ileocolon (L3) 6 (54.6%) </p> <p>Upper GI (L4) 0 (0.0%)<br/>Control:<br/>Ileum (L1): 1 (9.1%) </p> <p>Colon (L2): 3 (27.3%)</p> <p>Ileocolon (L3): 7 (63.6%)</p> <p>Upper GI (L4) 0 (0.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Previous and concomitant medications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at least one complete</p> <p>course of antibiotics with a seton placement or conventional</p> <p>surgery (advancement flap or fistulectomy), at</p> <p>least one complete induction course of infliximab, unless</p> <p>anti‐TNF‐α treatment was contraindicated</p> <p><b>Concomitant</b>: any except infliximab, tacrolimus, or cyclosporine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mesalamine, steroids, anti TNF, immunosuppressives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminosalicylates‐corticosteroids‐immunomodulators‐biologics (at least 3m before study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>concomitant but refractory to immunomodulatory and anti‐TNF and antibiotics at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids for the last 6 months and as background treatment</p> <p>Anticoagulation prior to treatment (2,500 IU of low‐molecular‐weight heparin )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I/P</p> <p>Prior drugs:</p> <p>Azathioprine/6MP:22/22</p> <p>Methotrexate:19/18</p> <p>Anti TNF:23/22</p> <p>Other:10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During the study, all patients received</p> <p>aminosalicylic acid (Mesalazine) and probiotic treatment.</p> <p>One patient in the observation group and three patients in</p> <p>the control group received immunomodulator treatment.</p> <p>One patient in each group was given antibiotics.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Previous bowel surgeries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (adv flap or fistulectomy)</p> <p>Previous fistula surgery: 39/49<br/>I= 17, P= 22 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:12</p> <p>P:9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 2/23</p> <p>P: 2/22</p> <p>Ileostomy:</p> <p>I: 4/23</p> <p>P: 4/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This clinical trial has been sponsored by Cellerix S.L.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This work was supported by the DigestScience Foundation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the study is funded by Celularity Incorporated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study was funded by TiGenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study was sponsored by<br/>the European Group for Blood and Marrow<br/>Transplantation (EBMT) Autoimmune Diseases<br/>Working Party and the European Crohn and Colitis<br/>Organisation (ECCO). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This work was funded by Key Medical Science and Technology Development</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Data here are not mentioned in the characteristics of the studies.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data Extracted from the included studies:</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/full#CD013070-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013070-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stem cells versus Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Stem cell therapy versus placebo or control, Outcome: Clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.80, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 CDAI &lt;150 at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Stem cell therapy versus placebo or control, Outcome: Fistula Closure short‐term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.12, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Stem cell therapy versus placebo or control, Outcome: Fistula closure in long‐term Follow up of original studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.09, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 PDAI Change at week 12 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 PDAI change at week 24 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.57, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 CDAI change at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Harvey Bradshow Index (HBI) change after 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.59 [‐4.04, ‐1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Endoscopic score change after 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Total Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Serious Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.88, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.32, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.51 [0.30, 101.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Quality of life score (change from base line) IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.18, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stem cells versus Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013070.pub2/references#CD013070-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013070.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013070-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013070-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013070-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013070-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013070-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013070-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013070-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013070-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013070\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013070\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013070\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013070\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013070\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013070.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013070.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013070.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013070.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013070.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729797294"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013070.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729797298"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013070.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee5a94d36f4d2',t:'MTc0MDcyOTc5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 